U.S. patent application number 11/118295 was filed with the patent office on 2005-11-03 for beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions.
This patent application is currently assigned to Boehringer Ingelheim International GmbH. Invention is credited to Hamilton, Bradford S., Trieselmann, Thomas.
Application Number | 20050245526 11/118295 |
Document ID | / |
Family ID | 34967644 |
Filed Date | 2005-11-03 |
United States Patent
Application |
20050245526 |
Kind Code |
A1 |
Trieselmann, Thomas ; et
al. |
November 3, 2005 |
Beta-agonists, methods for the preparation thereof and their use as
pharmaceutical compositions
Abstract
The present invention relates to new beta-agonists of general
formula (I) 1 wherein the groups R.sup.1 to R.sup.7 have the
meanings given in the claims and specification, the tautomers, the
enantiomers, the diastereomers, the mixtures thereof, the prodrugs
thereof and the salts thereof, particularly the physiologically
acceptable salts thereof with inorganic or organic acids or bases,
processes for preparing these compounds and their use as
pharmaceutical compositions.
Inventors: |
Trieselmann, Thomas;
(Warthausen, DE) ; Hamilton, Bradford S.;
(Biberach, DE) |
Correspondence
Address: |
MICHAEL P. MORRIS
BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD
CT
06877-0368
US
|
Assignee: |
Boehringer Ingelheim International
GmbH
Ingelheim
DE
|
Family ID: |
34967644 |
Appl. No.: |
11/118295 |
Filed: |
April 29, 2005 |
Current U.S.
Class: |
514/249 ;
514/341; 514/372; 514/381; 514/383; 514/394; 514/397; 514/398;
544/354; 548/253; 548/304.7; 548/311.1; 548/335.5 |
Current CPC
Class: |
C07D 401/04 20130101;
A61P 3/06 20180101; C07D 409/04 20130101; C07D 413/04 20130101;
C07D 249/06 20130101; C07D 249/08 20130101; A61P 43/00 20180101;
C07D 233/64 20130101; A61P 3/10 20180101; C07D 233/90 20130101;
A61P 3/04 20180101; A61P 3/00 20180101; C07D 233/36 20130101; A61P
13/10 20180101; C07D 403/10 20130101; A61P 1/14 20180101; C07D
235/06 20130101; C07D 237/32 20130101; C07D 233/68 20130101; A61P
25/24 20180101 |
Class at
Publication: |
514/249 ;
514/398; 514/341; 514/372; 514/394; 514/383; 514/397; 544/354;
548/304.7; 548/311.1; 548/335.5; 514/381; 548/253 |
International
Class: |
A61K 031/498; A61K
031/4196; A61K 031/4178; A61K 031/4184; C07D 049/14; C07D 043/02;
A61K 031/425 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 30, 2004 |
DE |
10 2004 021 779 |
Claims
What is claimed is:
1. A compound of the formula 83wherein R.sup.1 denotes an
optionally substituted aryl or heteroaryl group, R.sup.2 denotes an
optionally substituted heteroaryl or heterocyclyl group, where
R.sup.2 contains at least one nitrogen atom, R.sup.3 and R.sup.4
independently of one another denote a hydrogen atom or an
optionally substituted group selected from among
C.sub.1-C.sub.5-alkyl, C.sub.3-C.sub.6-cycloalkyl, heterocyclyl,
aryl and heteroaryl, or R.sup.3 and R.sup.4 together represent a 2-
to 7-membered alkylene bridge, R.sup.5, R.sup.6 and R.sup.7
independently of one another denote a hydrogen atom or a group
selected from among optionally substituted C.sub.1-C.sub.10-alkyl,
alkenyl, alkynyl, C.sub.6-C.sub.10-aryl, heterocyclyl,
C.sub.3-C.sub.8-cycloalkyl, --NR.sup.8--C.sub.1-C.sub.5-alkyl,
--NR.sup.8-aryl, halogen, CN,
--NR.sup.8CO--(C.sub.1-C.sub.5-alkyl), --NR.sup.8CO-aryl,
--NR.sup.8SO.sub.2--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2-aryl, --CO.sub.2R.sup.8, --SO.sub.2R.sup.8,
--CONHR.sup.8, --SO.sub.2NHR.sup.8 and --OR.sup.8, while the
above-mentioned alkyl groups may be substituted in each case, and
R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl group,
or a tautomer or pharmaceutically acceptable salt thereof.
2. A compound of the formula (I) according to claim 1, wherein
R.sup.2 to R.sup.7 are defined as in claim 1, and R.sup.1 denotes
an optionally substituted phenyl group, or a tautomer or
pharmaceutically acceptable salt thereof.
3. A compound of the formula (I) according to claim 1, wherein
R.sup.1 and R.sup.3 to R.sup.7 are defined as in claim 1, and
R.sup.2 denotes a group selected from among the optionally
substituted groups of formulae: 84while the above-mentioned groups
may each be substituted by one or more groups R.sup.10 and R.sup.10
denotes OH, NO.sub.2, CN, --OCHF.sub.2, --OCF.sub.3, --NH.sub.2,
--NH-alkyl, --N(-alkyl)-alkyl, --NH-aryl, --N(-alkyl)-aryl,
--NHCO-alkyl, --NHCO.sub.2-alkyl, --NHCO-aryl,
--N(-alkyl)-CO-alkyl, --N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl,
--NHSO.sub.2-aryl, --N(-alkyl)-SO.sub.2-alkyl,
--N(-alkyl)-SO.sub.2-aryl, --CO.sub.2-alkyl, --SO.sub.2-alkyl,
--SO.sub.2-aryl, --CON H-alkyl, --CONH-aryl, --CON(-alkyl)-alkyl,
--CON(-alkyl)-aryl, --SO.sub.2NH-alkyl, --SO.sub.2NH-aryl,
--SO.sub.2N(-alkyl)-alkyl, --SO.sub.2N(-alkyl)-aryl, --O-alkyl,
--O-aryl, --S-alkyl, --S-aryl, halogen, C.sub.1-C.sub.10-alkyl,
--O--(C.sub.1-C.sub.3-alkyl), --COOH, --CONH.sub.2,
--CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl, --CONHOH,
2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-- oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl, and wherein X denotes an oxygen atom or an --NR.sup.9--
group and Y denotes an oxygen or sulphur atom, and R.sup.9 denotes
a hydrogen atom or a group selected from among
C.sub.1-C.sub.10-alkyl, C.sub.3-C.sub.8-cycloalkyl, heterocyclyl,
aryl or heteroaryl, while the groups mentioned for R.sup.9
hereinbefore may each be substituted by one of the groups mentioned
for R.sup.10, or a tautomer or pharmaceutically acceptable salt
thereof.
4. A compound of the formula I, according to claim 1, wherein
R.sup.3 and R.sup.4 independently of one another represent a
hydrogen atom or a methyl or ethyl group or R.sup.3 and R.sup.4
together represent a 2- to 5-membered alkylene bridge, or a
tautomer or pharmaceutically acceptable salt thereof.
5. A compound of the formula I, according to claim 2, wherein
R.sup.3 and R.sup.4 independently of one another represent a
hydrogen atom or a methyl or ethyl group or R.sup.3 and R.sup.4
together represent a 2- to 5-membered alkylene bridge, or a
tautomer or pharmaceutically acceptable salt thereof.
6. A compound of the formula I, according to claim 3, wherein
R.sup.3 and R.sup.4 independently of one another represent a
hydrogen atom or a methyl or ethyl group or R.sup.3 and R.sup.4
together represent a 2- to 5-membered alkylene bridge, or a
tautomer or pharmaceutically acceptable salt thereof.
7. A compound of the formula I, according to claim 1 wherein,
R.sup.5, R.sup.6 and R.sup.7 independently of one another represent
hydrogen, optionally substituted C.sub.1-C.sub.10-alkyl, halogen,
CN, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2--(C.sub.1-C.sub- .5-alkyl), --CO.sub.2R.sup.8,
--SO.sub.2R.sup.8, --CONHR.sup.8, --SO.sub.2NHR.sup.8 or --OR.sup.8
and R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group, or a tautomer or pharmaceutically acceptable salt
thereof.
8. A compound of the formula I, according to claim 2, wherein,
R.sup.5, R.sup.6 and R.sup.7 independently of one another represent
hydrogen, optionally substituted C.sub.1-C.sub.10-alkyl, halogen,
CN, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2--(C.sub.1-C.sub- .5-alkyl), --CO.sub.2R.sup.8,
--SO.sub.2R.sup.8, --CONHR.sup.8, --SO.sub.2NHR.sup.8 or --OR.sup.8
and R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group, or a tautomer or pharmaceutically acceptable salt
thereof.
9. A compound of the formula I, according to claim 3, wherein,
R.sup.5, R.sup.6 and R.sup.7 independently of one another represent
hydrogen, optionally substituted C.sub.1-C.sub.10-alkyl, halogen,
CN, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2--(C.sub.1-C.sub- .5-alkyl), --CO.sub.2R.sup.8,
--SO.sub.2R.sup.8, --CONHR.sup.8, --SO.sub.2NHR.sup.8 or --OR.sup.8
and R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group, or a tautomer or pharmaceutically acceptable salt
thereof.
10. A compound of the formula I, according to claim 4, wherein,
R.sup.5, R.sup.6 and R.sup.7 independently of one another represent
hydrogen, optionally substituted C.sub.1-C.sub.10-alkyl, halogen,
CN, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2--(C.sub.1-C.sub- .5-alkyl), --CO.sub.2R.sup.8,
--SO.sub.2R.sup.8, --CONHR.sup.8, --SO.sub.2NHR.sup.8 or --OR.sup.8
and R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group, or a tautomer or pharmaceutically acceptable salt
thereof.
11. A compound of the formula I, according to claim 1, wherein,
R.sup.1 denotes a phenyl group optionally substituted by a halogen
atom or a cyano or nitro group, R.sup.2 denotes a group selected
from among the optionally substituted groups of formulae 85while
the above-mentioned groups may each be substituted by one or more
groups R.sup.10 and R.sup.10 denotes OH, NO.sub.2, CN,
--OCHF.sub.2, --OCF.sub.3, --NH.sub.2, --NH-alkyl,
--N(-alkyl)-alkyl, --NH-aryl, --N(-alkyl)-aryl, --NHCO-alkyl,
--NHCO.sub.2-alkyl, --NHCO-aryl, --N(-alkyl)CO-alkyl,
--N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl, --NHSO.sub.2-aryl,
--N(-alkyl)-SO.sub.2-alkyl, --N(-alkyl)-SO.sub.2-aryl,
--CO.sub.2-alkyl, --SO.sub.2-alkyl, --SO.sub.2-aryl, --CONH-alkyl,
--CONH-aryl, --CON(alkyl)-alkyl, --CON(-alkyl)-aryl,
--SO.sub.2NH-alkyl, --SO.sub.2NH-aryl, --SO.sub.2N(-alkyl)-alkyl,
--SO.sub.2N(-alkyl)-aryl, --O-aryl, --S-alkyl, --S-aryl, halogen,
C.sub.1-C.sub.10-alkyl, --O--(C.sub.1-C.sub.3-alkyl), --COOH,
--CONH.sub.2, --CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl,
--CONHOH, 2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thi- adiazol-3-yl,
2,5-dihydro-2-oxo-3H-1, 2,4,5-oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl, and wherein X denotes an oxygen atom or an --NR.sup.9--
group and Y denotes an oxygen or sulphur atom, R.sup.3 and R.sup.4
independently of one another each denote a methyl or ethyl group or
R.sup.3 and R.sup.4 together represent an ethylene bridge, R.sup.5,
R.sup.6 and R.sup.7 independently of one another each denote a
hydrogen, fluorine or chlorine atom or a cyano, methoxy,
methanesulphonylamino, methanesulphonyl, difluoromethoxy,
trifluoromethoxy, difluoromethyl or trifluoromethyl group, R.sup.9
denotes a hydrogen atom or an optionally substituted aryl or
optionally substituted heteroaryl group, or a tautomer or
pharmaceutically acceptable salt thereof.
12. A compound of the formula (I) according to claim 1, wherein
R.sup.1 denotes a phenyl group optionally substituted by a
fluorine, chlorine, bromine or iodine atom or a cyano or nitro
group, R.sup.2 denotes a group selected from among the optionally
substituted groups of general formulae (i)-(vi): 86where R.sup.9
denotes a phenyl or pyridyl group optionally substituted by a
fluorine atom or by an amino, nitro, hydroxy or methoxy group and
the above-mentioned groups (i) to (vi) may each be substituted by
one or two groups R.sup.10 and R.sup.10 denotes OH, NO.sub.2, CN,
--OCHF.sub.2, --OCF.sub.3, --NH.sub.2, --NH-alkyl,
--N(alkyl)-alkyl, --NH-aryl, --N(alkyl)-aryl, --NHCO-alkyl,
--NHCO.sub.2-alkyl, --NHCO-aryl, --N(-alkyl)-CO-alkyl,
--N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl, --NHSO.sub.2-aryl,
--N(-alkyl)-SO.sub.2-alkyl, --N(-alkyl)-SO.sub.2-aryl,
--CO.sub.2-alkyl, --SO.sub.2-alkyl, --SO.sub.2-aryl, --CONH-alkyl,
--CONH-aryl, --CON(alkyl)-alkyl, --CON(-alkyl)-aryl,
--SO.sub.2NH-alkyl, --SO.sub.2NH-aryl, --SO.sub.2N(-alkyl)-alkyl,
--SO.sub.2N(-alkyl)-aryl, --O-aryl, --S-alkyl, --S-aryl, halogen,
C.sub.1-C.sub.10-alkyl, --O--(C.sub.1-C.sub.3-alkyl), --COOH,
--CONH.sub.2, --CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl,
--CONHOH, 2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-- oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl, R.sup.3 and R.sup.4 independently of one another denote
a methyl or ethyl group or R.sup.3 and R.sup.4 together represent
an ethylene bridge and R.sup.5, R.sup.6 and R.sup.7 represent a
hydrogen, fluorine or chlorine atom or a cyano, methoxy,
methanesulphonylamino, methanesulphonyl, difluoromethoxy,
trifluoromethoxy, difluoromethyl or trifluoromethyl group, or a
tautomer or pharmaceutically acceptable salt thereof.
13. A compound of the formula (I) according to claim 12, wherein
R.sup.1 denotes a phenyl group optionally substituted by a
fluorine, chlorine, bromine or iodine atom or by a cyano or nitro
group, R.sup.2 denotes a group selected from among the groups of
formulae (i)-(vi): 87where R.sup.9 denotes a phenyl or pyridyl
group optionally substituted by a fluorine atom or by an amino,
nitro, hydroxy or methoxy group, and the above-mentioned groups (i)
to (vi) may each be substituted by one or two groups R.sup.10 and
R.sup.10 denotes OH, --NO.sub.2, --CN, --NH.sub.2, --I,
--N(CH.sub.3).sub.2, --NHCO.sub.2CH.sub.3, --NHSO.sub.2CH.sub.3,
C.sub.1-C.sub.3-alkyl, --SO.sub.2N(CH.sub.3).sub.2, --CO.sub.2H,
benzyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, --CONHOH,
tetrazol-5-yl, pyridinyl, methoxy-pyridinyl, phenyl optionally
substituted by hydroxy, fluorine, methoxy, amino, nitro,
dimethylamino, methylcarbonylamino, methylsulphonylamino,
dimethylamino-sulphonylamino, carboxy, ethoxycarbonyl,
benzyloxy-carbonyl, hydroxyaminocarbonyl or tetrazol-5-yl, or
thiophenyl, 5-methyl-thiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl or
1-acetyl-2-amino-propenyl, R.sup.3 and R.sup.4 each denote a methyl
or ethyl group or R.sup.3 and R.sup.4 together represent an
ethylene bridge and R.sup.5, R.sup.6 and R.sup.7 each denote a
hydrogen atom, or a tautomer or pharmaceutically acceptable salt
thereof.
14. A compound of the formula (I) according to claim 13, wherein
R.sup.1 denotes a phenyl group, R.sup.2 denotes a group selected
from among the groups of formulae (i)-(iii) or (v): 88where R.sup.9
denotes a phenyl or pyridyl group optionally substituted by a
fluorine atom or by an amino, nitro, hydroxy or methoxy group, and
the above-mentioned groups (i) to (iii) and (v) may each be
substituted by a group R.sup.10 and R.sup.10 denotes an iodine atom
or a nitro, amino, methyl, carboxy, methoxycarbonyl,
ethoxycarbonyl, pyridin-4-yl, pyridin-2-yl, 6-methoxy-pyridin-3-yl,
thiophen-2-yl, 5-methyl-thiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl,
1-acetyl-2-amino-propen-1-yl or a phenyl group, while the phenyl
group may be substituted by a fluorine atom or by a hydroxy,
methoxy, nitro, amino, dimethylamino, methylcarbonylamino,
methylsulphonylamino, dimethylamino-sulphonylamino, carboxy,
ethoxycarbonyl, benzyloxy-carbonyl, hydroxyaminocarbonyl or
tetrazol-5-yl group, R.sup.3 and R.sup.4 each denote a methyl group
and R.sup.5, R.sup.6 and R.sup.7 each denote a hydrogen atom, or a
tautomer or pharmaceutically acceptable salt thereof.
15. A compound of the formula (I) according to claim 14, wherein
R.sup.1 denotes a phenyl group, R.sup.2 denotes a group of formulae
(Ia) or (v): 89while the above-mentioned group (i) may be
substituted in the phenyl moiety by a fluorine atom or by a
hydroxy, methoxy, nitro, amino, dimethylamino, methylcarbonylamino,
methylsulphonylamino, dimethyl-amino-sulphonylamino, carboxy,
ethoxycarbonyl, benzyloxycarbonyl, hydroxyaminocarbonyl or
tetrazol-5-yl group and the above-mentioned group (v) may be
substituted in the benzyl moiety by a nitro, amino, carboxy or
C.sub.1-2-alkyloxy-carbonyl group, R.sup.3 and R.sup.4 each denote
a methyl group and R.sup.5, R.sup.6 and R.sup.7 each denote a
hydrogen atom, or a tautomer or pharmaceutically acceptable salt
thereof.
16. A compound selected from the group consisting of:
N-(3-{2-[1,1-dimethyl-3-(4-phenyl-imidazol-1-yl)-propylamino]-1-hydroxy-e-
thyl}-phenyl)-benzenesulphonamide,
N-(3-{2-[1,1-dimethyl-3-(3-methyl-1,4-d-
ioxo-3,4-dihydro-1H-phthalazin-2-yl)-propylamino]-1-hydroxy-ethyl}-phenyl)-
-benzenesulphonamide,
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-phenyl-imidazolidin-
-1-yl)-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide,
N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imidazol-1-yl]-propylamino}-1-
-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{3-[3-(4-fluoro-pheny-
l)-2-oxo-imidazolidin-1-yl]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phe-
nyl]-benzenesulphonamide,
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-imida-
zol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(1-hydroxy-2-{3-[4-(4-hydroxy-phenyl)-imidazol-1-yl]-1,1-dimethyl-pr-
opylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{3-[4-(4-amino-phen-
yl)-imidazol-1-yl]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benz-
enesulphonamide,
N-[3-(1-hydroxy-2-{3-[4-(4-methanesulphonylamino-phenyl)--
imidazol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamid-
e,
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propylamino]-e-
thyl}-phenyl)-benzenesulphonamide, methyl
1-{3-[2-(3-benzenesulphonylamino-
-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazole-4-carboxylate,
N-[3-(1-hydroxy-2-{3-[4-(4-N,N-dimethyl-sulphamoylamino-phenyl)-imidazol--
1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-pyridin-2-yl-imidazolidin-1-yl)-propylam-
ino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide,
1-{3-[2-(3-benzenesulph-
onylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazole-4-car-
boxylic acid,
N-(3-{2-[1,1-dimethyl-3-(4-pyridin-4-yl-imidazol-1-yl)-propy-
lamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide, benzyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methy-
l-butyl}-1H-imidazol-4-yl)-benzoate,
4-(1-{3-[2-(3-benzenesulphonylamino-p-
henyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoic
acid,
N-[3-(1-hydroxy-2-{3-[3-(4-hydroxy-phenyl)-2-oxo-imidazolidin-1-yl]-
-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-[4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-me-
thyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetamide,
N-[3-(2-{3-[4-(3,5-dimeth-
yl-isoxazol-4-yl)-imidazol-1-yl]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl-
)-phenyl]-benzenesulphonamide,
N-[3-(1-hydroxy-2-{3-[4-(6-methoxy-pyridin--
3-yl)-imidazol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulph-
onamide,
N-[3-(2-{1,1-dimethyl-3-[4-(5-methyl-thiophen-2-yl)-imidazol-1-yl-
]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{3-[4-(4-fluoro-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylamino}--
1-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-(3-{2-[1,1-dimethyl-3-(5-n-
itro-benzoimidazol-1-yl)-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulp-
honamide,
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-[1.2.3]triazol-1-yl]--
1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-(3-{2-[1,1-dimethyl-3-(4-thiophen-2-yl-imidazol-1-yl)-propylamino]-1-hy-
droxy-ethyl}-phenyl)-benzenesulphonamide,
N-[3-(2-{3-[4-(4-dimethylamino-p-
henyl)-imidazol-1-yl]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-b-
enzenesulphonamide, ethyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hy-
droxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate,
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-d-
imethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{1,1-dimethyl-3-[3-(4-nitro-phenyl)-2-oxo-imidazolidin-1-yl]-prop-
ylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-5-methyl-[1,2,4]triazol-1-yl]--
1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{3-[3-(4-amino-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimethyl-prop-
ylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-[3-(2-{3-[4-(1-acetyl-2-amino-propenyl)-imidazol-1-yl]-1,1-dimethyl-pro-
pylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide,
N-(3-{2-[3-(5-amino-benzoimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydro-
xy-ethyl}-phenyl)-benzenesulphonamide,
1-{3-[2-(3-benzenesulphonylamino-ph-
enyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-benzoimidazole-5-carboxylic
acid, ethyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino-
]-3-methyl-butyl}-1H-benzoimidazole-5-carboxylate,
N-{3-[2-(1,1-dimethyl-3-
-{4-[4-(1H-tetrazol-5-yl)-phenyl]-imidazol-1-yl}-propylamino)-1-hydroxy-et-
hyl]-phenyl}-benzenesulphonamide, and
4-(1-{3-[2-(3-benzenesulphonylamino--
phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-N-hydroxy--
benzamide, or a pharmaceutically acceptable salt thereof.
17. The (R)-enantiomer of a compound according to claim 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, or a pharmaceutically
acceptable salt thereof.
18. A pharmaceutical composition comprising a compound of the
formula I according to claim 1, or a pharmaceutically acceptable
salt thereof, together with a pharmaceutically acceptable carrier
or excipient.
19. A method for treating a disease in which stimulation of
beta-3-receptors is implicated which method comprises administering
to a host in need of such treatment a compound of the formula I
according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15 or 16, or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition containing as active substance a
compound of the formula (I) according to claim 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15 or 16, or a pharmaceutically
acceptable salt thereof, and one or more active substances selected
from the group consisting of antidiabetics, inhibitors of protein
tyrosinephosphatase 1, substances which influence deregulated
glucose production in the liver, lipid lowering agents, cholesterol
absorption inhibitors, HDL-raising compounds, active substances for
the treatment of obesity and modulators or stimulators of the
adrenergic system via alpha 1 and alpha 2 as well as beta 1, beta 2
and beta 3 receptors.
Description
[0001] The present invention relates to new beta-agonists of
general formula (I) 2
[0002] wherein the groups R.sup.1 to R.sup.7 have the meanings
given below in the specification, the tautomers, the enantiomers,
the diastereomers, the mixtures thereof, the prodrugs thereof and
the salts thereof, particularly the physiologically acceptable
salts thereof with inorganic or organic acids or bases, processes
for preparing these compounds and their use as pharmaceutical
compositions.
BACKGROUND OF THE INVENTION
[0003] The treatment of type II diabetes and obesity is based
primarily on reducing calorie intake and increasing physical
activity. These methods are rarely successful in the longer
term.
[0004] It is known that beta-3 receptor agonists have a significant
effect on lipolysis, thermogenesis and the serum glucose level in
animal models of type II diabetes (Arch J R. beta(3)-Adrenoceptor
agonists: potential, pitfalls and progress, Eur J. Pharmacol. 2002
Apr. 12; 440(2-3):99-107).
[0005] Compounds which are structurally similar to the compounds
according to the invention and their broncholytic, spasmolytic and
antiallergic activities were disclosed in DE 2833140, for
example.
[0006] The aim of the present invention is to provide selective
beta-3 agonists which can be used to prepare pharmaceutical
compositions for the treatment of obesity and type II diabetes.
DETAILED DESCRIPTION OF THE INVENTION
[0007] Surprisingly it has been found that compounds of general
formula (I) wherein the groups R.sup.1 to R.sup.7 are defined as
hereinafter are effective as selective beta-3 agonists. Thus, the
compounds according to the invention may be used to treat diseases
connected with the stimulation of beta-3-receptors.
[0008] The present invention therefore relates to compounds of
general formula (I) 3
[0009] wherein
[0010] R.sup.1 denotes an optionally substituted aryl or heteroaryl
group,
[0011] R.sup.2 denotes an optionally substituted heteroaryl or
heterocyclyl group, while R.sup.2 contains at least one nitrogen
atom,
[0012] R.sup.3 and R.sup.4 independently of one another denote a
hydrogen atom or an optionally substituted group selected from the
group comprising C.sub.1-C.sub.5-alkyl, C.sub.3-C.sub.6-cycloalkyl,
heterocyclyl, aryl and heteroaryl or
[0013] R.sup.3 and R.sup.4 together represent a 2- to 7-membered
alkylene bridge,
[0014] R.sup.5, R.sup.6 and R.sup.7 independently of one another
denote a hydrogen atom or a group selected from the group
comprising optionally substituted C.sub.1-C.sub.10-alkyl, alkenyl,
alkynyl, C.sub.6-C.sub.10-aryl, heterocyclyl,
C.sub.3-C.sub.8-cycloalkyl, --NR.sup.8--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8-aryl, halogen, cyano,
--NR.sup.8CO--(C.sub.1-C.sub.5-alkyl), --NR.sup.8CO-aryl,
--NR.sup.8SO.sub.2--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2-aryl, --CO.sub.2R.sup.8, --SO.sub.2R.sup.8,
--CONHR.sup.8, --SO.sub.2NHR.sup.8 and --OR.sup.8, while the
abovementioned alkyl groups may be substituted in each case,
and
[0015] R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group,
[0016] optionally in the form of the tautomers, racemates,
enantiomers, diastereomers, solvates and hydrates thereof and the
mixtures thereof, as well as optionally the prodrugs, double
prodrugs and salts thereof, particularly the physiologically
acceptable salts thereof with inorganic or organic acids or
bases.
[0017] Preferred are compounds of general formula (I), wherein
[0018] R.sup.2 to R.sup.7 are as hereinbefore defined and
[0019] R.sup.1 denotes an optionally substituted phenyl group.
[0020] Another preferred sub-group relates to the compounds of
general formula (I), wherein
[0021] R.sup.1 and R.sup.3 to R.sup.7 are as hereinbefore
defined,
[0022] R.sup.2 denotes a group selected from among the optionally
substituted groups of formulae: 4
[0023] while the above-mentioned groups may be substituted in each
case by one or more groups R.sup.10 and
[0024] R.sup.10 denotes OH, NO.sub.2, CN, --OCHF.sub.2,
--OCF.sub.3, --NH.sub.2, --NH-alkyl, --N(-alkyl)-alkyl, --NH-aryl,
--N(-alkyl)-aryl, --NHCO-alkyl, --NHCO.sub.2-alkyl, --NHCO-aryl,
--N(-alkyl)-CO-alkyl, --N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl,
--NHSO.sub.2-aryl, --N(-alkyl)-SO.sub.2-alkyl,
--N(-alkyl)-SO.sub.2-aryl, --CO.sub.2-alkyl, --SO.sub.2-alkyl,
--SO.sub.2-aryl, --CON H-alkyl, --CONH-aryl, --CON(-alkyl)-alkyl,
--CON(-alkyl)-aryl, --SO.sub.2NH-alkyl, --SO.sub.2NH-aryl,
--SO.sub.2N(-alkyl)-alkyl, --SO.sub.2N(-alkyl)-aryl, --O-alkyl,
--O-aryl, --S-alkyl, --S-aryl, halogen, C.sub.1-C.sub.10-alkyl,
--O--(C.sub.1-C.sub.3-alkyl), --COOH, --CONH.sub.2,
--CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl, --CONHOH,
2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-- oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl,
[0025] and wherein X denotes an oxygen atom or a --NR.sup.9-- group
and
[0026] Y denotes an oxygen or sulphur atom,
[0027] and R.sup.9 denotes a hydrogen atom or a group selected from
the group comprising C.sub.1-C.sub.10-alkyl,
C.sub.3-C.sub.8-cycloalkyl, heterocyclyl, aryl or heteroaryl, while
the groups mentioned for R.sup.9 hereinbefore may each case be
substituted by one of the groups given for R.sup.10.
[0028] Particularly preferred are compounds of general formula (I),
wherein
[0029] R.sup.1 and R.sup.2 as well as R.sup.5 to R.sup.7 are as
hereinbefore defined, and
[0030] R.sup.3 and R.sup.4 independently of one another denote a
hydrogen atom or a methyl or ethyl group or
[0031] R.sup.3 and R.sup.4 together represent a 2- to 5-membered
alkylene bridge.
[0032] Particularly preferred are compounds of general formula (I),
wherein
[0033] R.sup.1 to R.sup.4 are as hereinbefore defined, and
[0034] R.sup.5, R.sup.6 and R.sup.7 independently of one another
represent hydrogen, optionally substituted C.sub.1-C.sub.10-alkyl,
halogen, CN, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2--(C.sub.1-C.sub- .5-alkyl), --CO.sub.2R.sup.8,
--SO.sub.2R.sup.8, --CONHR.sup.8, --SO.sub.2NHR.sup.8 or --OR.sup.8
and
[0035] R.sup.8 denotes a hydrogen atom or a C.sub.1-C.sub.5-alkyl
group.
[0036] Also preferred are compounds of general formula (I),
wherein
[0037] R.sup.1 denotes a phenyl group optionally substituted by a
halogen atom or a cyano or nitro group,
[0038] R.sup.2 denotes a group selected from among the optionally
substituted groups of formulae: 5
[0039] while the above-mentioned groups may each be substituted by
one or more groups R.sup.10 and
[0040] R.sup.10 denotes OH, NO.sub.2, CN, --OCHF.sub.2,
--OCF.sub.3, --NH.sub.2, --NH-alkyl, --N(-alkyl)-alkyl, --NH-aryl,
--N(-alkyl)-aryl, --NHCO-alkyl, --NHCO.sub.2-alkyl, --NHCO-aryl,
--N(-alkyl)CO-alkyl, --N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl,
--NHSO.sub.2-aryl, --N(-alkyl)-SO.sub.2-alkyl,
--N(-alkyl)-SO.sub.2-aryl, --CO.sub.2-alkyl, --SO.sub.2-alkyl,
--SO.sub.2-aryl, --CONH-alkyl, --CON H-aryl, --CON(alkyl)-alkyl,
--CON(-alkyl)-aryl, --SO.sub.2N H-alkyl, --SO.sub.2NH-aryl,
--SO.sub.2N(-alkyl)-alkyl, --SO.sub.2N(-alkyl)-aryl, --O-aryl,
--S-alkyl, --S-aryl, halogen, C.sub.1-C.sub.10-alkyl,
--O--(C.sub.1-C.sub.3-alkyl), --COOH, --CONNH.sub.2,
--CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl, --CONHOH,
2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thi- adiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl,
[0041] and wherein X denotes an oxygen atom or a --NR.sup.9-- group
and
[0042] Y denotes an oxygen or sulphur atom,
[0043] R.sup.3 and R.sup.4 independently of one another each denote
a methyl or ethyl group or
[0044] R.sup.3 and R.sup.4 together represent an ethylene
bridge,
[0045] R.sup.5, R.sup.6 and R.sup.7 independently of one another
each denote a hydrogen, fluorine or chlorine atom or a cyano,
methoxy, methanesulphonylamino, methanesulphonyl, difluoromethoxy,
trifluoromethoxy, difluoromethyl or trifluoromethyl group and
[0046] R.sup.9 denotes a hydrogen atom or an optionally substituted
aryl or optionally substituted heteroaryl group.
[0047] Particularly preferred are compounds of general formula (I),
wherein
[0048] R.sup.1 denotes a phenyl group optionally substituted by a
fluorine, chlorine, bromine or iodine atom or a cyano or nitro
group,
[0049] R.sup.2 denotes a group selected from among the groups of
formulae (i)-(vi): 6
[0050] where R.sup.9 denotes a phenyl or pyridyl group optionally
substituted by a fluorine atom or by an amino, nitro, hydroxy or
methoxy group and the above-mentioned groups (i) to (vi) may each
be substituted by one or two groups R.sup.10 and
[0051] R.sup.10 denotes OH, NO.sub.2, CN, --OCHF.sub.2,
--OCF.sub.3, --NH.sub.2, --NH-alkyl, --N(alkyl)-alkyl, --NH-aryl,
--N(alkyl)-aryl, --NHCO-alkyl, --NHCO.sub.2-alkyl, --NHCO-aryl,
--N(-alkyl)-CO-alkyl, --N(-alkyl)-CO-aryl, --NHSO.sub.2-alkyl,
--NHSO.sub.2-aryl, --N(-alkyl)-SO.sub.2-alkyl,
--N(-alkyl)-SO.sub.2-aryl, --CO.sub.2-alkyl, --SO.sub.2-alkyl,
--SO.sub.2-aryl, --CONH-alkyl, --CONH-aryl, --CON(alkyl)-alkyl,
--CON(-alkyl)-aryl, --SO.sub.2NH-alkyl, --SO.sub.2NH-aryl,
--SO.sub.2N(-alkyl)-alkyl, --SO.sub.2N(-alkyl)-aryl, --O-aryl,
--S-alkyl, --S-aryl, halogen, C.sub.1-C.sub.10-alkyl,
--O--(C.sub.1-C.sub.3-alkyl), --COOH, --CONH.sub.2,
--CON(-alkyl)-SO.sub.2-alkyl, --CONHSO.sub.2-alkyl, --CONHOH,
2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thi- adiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-oxathiadiazol-4-yl,
1-acetyl-2-amino-propen-1-yl, tetrazolyl, heterocyclyl, aryl or
heteroaryl,
[0052] R.sup.3 and R.sup.4 independently of one another denote a
methyl or ethyl group or
[0053] R.sup.3 and R.sup.4 together represent an ethylene bridge
and
[0054] R.sup.5, R.sup.6 and R.sup.7 independently of one another
denote a hydrogen, fluorine or chlorine atom or a cyano, methoxy,
methanesulphonylamino, methanesulphonyl, difluoromethoxy,
trifluoromethoxy, difluoromethyl or trifluoromethyl group.
[0055] Particularly preferred are compounds of general formula (I),
wherein
[0056] R.sup.1 denotes a phenyl group optionally substituted by a
fluorine, chlorine, bromine or iodine atom or a cyano or nitro
group,
[0057] R.sup.2 denotes a group selected from among the groups of
formulae (i)-(vi): 7
[0058] where R.sup.9 denotes a phenyl or pyridyl group optionally
substituted by a fluorine atom or by an amino, nitro, hydroxy or
methoxy group,
[0059] and the above-mentioned groups (i) to (vi) may each be
substituted by one or two groups R.sup.10 and
[0060] R.sup.10 denotes OH, --NO.sub.2, --CN, --NH.sub.2, --I,
--N(CH.sub.3).sub.2, --NHCO.sub.2CH.sub.3, --NHSO.sub.2CH.sub.3,
C.sub.1-C.sub.3-alkyl, --SO.sub.2N(CH.sub.3).sub.2, --CO.sub.2H,
benzyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, --CONHOH,
tetrazol-5-yl, pyridinyl, methoxy-pyridinyl, phenyl optionally
substituted by hydroxy, fluorine, methoxy, amino, nitro,
dimethylamino, methylcarbonylamino, methylsulphonylamino,
dimethylamino-sulphonylamino, carboxy, ethoxycarbonyl,
benzyloxy-carbonyl, hydroxyaminocarbonyl or tetrazol-5-yl, or
thiophenyl, 5-methylthiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl or
1-acetyl-2-amino-propenyl,
[0061] R.sup.3 and R.sup.4 in each case denote a methyl or ethyl
group or
[0062] R.sup.3 and R.sup.4 together represent an ethylene bridge
and
[0063] R.sup.5, R.sup.6 and R.sup.7 in each case denote a hydrogen
atom.
[0064] Particular emphasis should be placed on compounds of general
formula (I), wherein
[0065] R.sup.1 denotes a phenyl group,
[0066] R.sup.2 denotes a group selected from among the groups of
formulae (i)-(iii) or (v): 8
[0067] while R.sup.9 denotes a phenyl or pyridyl group optionally
substituted by a fluorine atom or an amino, nitro, hydroxy or
methoxy group,
[0068] and the above-mentioned groups (i) to (iii) and (v) may each
be substituted by a group R.sup.10 and
[0069] R.sup.10 denotes an iodine atom or a nitro, amino, methyl,
carboxy, methoxycarbonyl, ethoxycarbonyl, pyridin-4-yl,
pyridin-2-yl, 6-methoxypyridin-3-yl, thiophen-2-yl,
5-methyl-thiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl,
1-acetyl-2-amino-propen-1-yl or a phenyl group, while the phenyl
group may be substituted, preferably in the 4 position, by a
fluorine atom or by a hydroxy, methoxy, nitro, amino,
dimethylamino, methylcarbonylamino, methylsulphonylamino,
dimethylamino-sulphonylamino, carboxy, ethoxycarbonyl,
benzyloxycarbonyl, hydroxyaminocarbonyl or tetrazol-5-yl group,
[0070] R.sup.3 and R.sup.4 in each case denote a methyl group
and
[0071] R.sup.5, R.sup.6 and R.sup.7 in each case denote a hydrogen
atom,
[0072] but especially those compounds of general formula (I),
wherein
[0073] R.sup.1 denotes a phenyl group,
[0074] R.sup.2 denotes a group of formulae (Ia) or (v): 9
[0075] while the above-mentioned group (i) may be substituted in
the phenyl moiety by a fluorine atom or by a hydroxy, methoxy,
nitro, amino, dimethylamino, methylcarbonylamino,
methylsulphonylamino, dimethylamino-sulphonylamino, carboxy,
ethoxycarbonyl, benzyloxycarbonyl, hydroxyaminocarbonyl or
tetrazol-5-yl group and
[0076] the above-mentioned group (v) may be substituted in the
benzyl moiety by a nitro, amino, carboxy or
C.sub.1-2-alkyloxy-carbonyl group,
[0077] R.sup.3 and R.sup.4 each denote a methyl group and
[0078] R.sup.5, R.sup.6 and R.sup.7 each denote a hydrogen
atom.
[0079] The following compounds are particularly preferred:
[0080]
N-(3-{2-[1,1-dimethyl-3-(4-phenyl-imidazol-1-yl)-propylamino]-1-hyd-
roxy-ethyl}-phenyl)-benzenesulphonamide
[0081]
N-(3-{2-[1,1-dimethyl-3-(3-methyl-1,4-dioxo-3,4-dihydro-1H-phthalaz-
in-2-yl)-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0082]
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-phenyl-imidazolidin-1-yl)-propylam-
ino]-1-hydroxyethyl}-phenyl)-benzenesulphonamide
[0083]
N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imidazol-1-yl]-propylam-
ino}-1-hydroxyethyl)-phenyl]-benzenesulphonamide
[0084]
N-[3-(2-{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimeth-
yl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0085]
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-imidazol-1-yl]-1,1-dimet-
hylpropylamino}-ethyl)-phenyl]-benzenesulphonamide
[0086]
N-[3-(1-hydroxy-2-{3-[4-(4-hydroxy-phenyl)-imidazol-1-yl]-1,1-dimet-
hylpropylamino}-ethyl)-phenyl]-benzenesulphonamide
[0087]
N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylam-
ino}-1-hydroxyethyl)-phenyl]-benzenesulphonamide
[0088]
N-[3-(1-hydroxy-2-{3-[4-(4-methanesulphonylamino-phenyl)-imidazol-1-
-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0089]
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propylamin-
o]-ethyl}-phenyl)-benzenesulphonamide
[0090] methyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamin-
o]-3-methyl-butyl}-1H-imidazole-4-carboxylate
[0091]
N-[3-(1-hydroxy-2-{3-[4-(4-N,N-dimethyl-sulphamoylamino-phenyl)-imi-
dazol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0092]
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-pyridin-2-yl-imidazolidin-1-yl)-pr-
opylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0093]
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-me-
thyl-butyl}-1H-imidazole-4-carboxylic acid
[0094]
N-(3-{2-[1,1-dimethyl-3-(4-pyridin-4-yl-imidazol-1-yl)-propylamino]-
-1-hydroxyethyl}-phenyl)-benzenesulphonamide
[0095] benzyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethyla-
mino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate
[0096]
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-
-methylbutyl}-1H-imidazol-4-yl)-benzoic acid
[0097]
N-[3-(1-hydroxy-2-{3-[3-(4-hydroxy-phenyl)-2-oxo-imidazolidin-1-yl]-
-1,1-dimethylpropylamino}-ethyl)-phenyl]-benzenesulphonamide
[0098]
N-[4-(-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-
-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetamide
[0099]
N-[3-(2-{3-[4-(3,5-dimethyl-isoxazol-4-yl)-imidazol-1-yl]-1,1-dimet-
hyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0100]
N-[3-(1-hydroxy-2-{3-[4-(6-methoxy-pyridin-3-yl)-imidazol-1-yl]-1,1-
-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0101]
N-[3-(2-{1,1-dimethyl-3-[4-(5-methyl-thiophen-2-yl)-imidazol-1-yl]--
propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0102]
N-[3-(2-{3-[4-(4-fluoro-phenyl)-imidazol-1-yl]-1,1-dimethyl-propyla-
mino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0103]
N-(3-{2-[1,1-dimethyl-3-(5-nitro-benzoimidazol-1-yl)-propylamino]-1-
-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0104]
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-[1,2,3]triazol-1-yl]-1,1-
-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0105]
N-(3-{2-[1,1-dimethyl-3-(4-thiophen-2-yl-imidazol-1-yl)-propylamino-
]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0106]
N-[3-(2-{3-[4-(4-dimethylamino-phenyl)-imidazol-1-yl]-1,1-dimethyl--
propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0107] ethyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylam-
ino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate
[0108]
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-2-oxo-imidazolidin-1-yl]-
-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0109]
N-[3-(2-{1,1-dimethyl-3-[3-(4-nitro-phenyl)-2-oxo-imidazolidin-1-yl-
]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0110]
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-5-methyl-[1,2,4]triazol--
1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0111]
N-[3-(2-{3-[3-(4-amino-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimethy-
l-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0112]
N-[3-(2-{3-[4-(1-acetyl-2-amino-propenyl)-imidazol-1-yl]-1,1-dimeth-
yl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0113]
N-(3-{2-[3-(5-amino-benzoimidazol-1-yl)-1,1-dimethyl-propylamino]-1-
-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0114]
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-me-
thyl-butyl}-1H-benzoimidazole-5-carboxylic acid
[0115] ethyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino-
]-3-methyl-butyl}-1H-benzoimidazole-5-carboxylate
[0116]
N-{3-[2-(1,1-dimethyl-3-{4-[4-(1H-tetrazol-5-yl)-phenyl]-imidazol-1-
-yl}-propylamino)-1-hydroxy-ethyl]-phenyl}-benzenesulphonamide
[0117]
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-
-methyl-butyl}-1H-imidazol-4-yl)-N-hydroxy-benzamide
[0118] The invention also relates to compounds of general formula
(I) for use as pharmaceutical compositions.
[0119] The invention also relates to compounds of general formula
(I) for use as pharmaceutical compositions with a selective
beta-3-agonistic activity.
[0120] The invention also relates to compounds of general formula
(I) for preparing a pharmaceutical composition for the treatment
and/or prevention of diseases connected with the stimulation of
beta-3-receptors.
[0121] The invention further relates to a method for the treatment
and/or prevention of diseases connected with the stimulation of
beta-3-receptors, in which a patient is given an effective amount
of a compound of general formula I.
[0122] The invention further relates to a pharmaceutical
composition containing as active substance one or more compounds of
general formula (I), optionally combined with conventional
excipients and/or carriers.
[0123] The invention further relates to a pharmaceutical
composition containing as active substance one or more compounds of
general formula (I) or the physiologically acceptable salts thereof
and one or more active substances selected from among
antidiabetics, inhibitors of protein tyrosinephosphatase 1,
substances which influence deregulated glucose production in the
liver, lipid lowering agents, cholesterol absorption inhibitors,
HDL-raising compounds, active substances for the treatment of
obesity and modulators or stimulators of the adrenergic system via
alpha 1 and alpha 2 as well as beta 1, beta 2 and beta 3
receptors.
[0124] The invention further relates to a process for preparing a
compound of general formula (I), 10
[0125] wherein
[0126] R.sup.1 to R.sup.7 may have the meanings given
hereinbefore,
[0127] where a compound of general formula (II) 11
[0128] wherein
[0129] R.sup.3 and R.sup.4 may have the meanings given
hereinbefore,
[0130] is converted by means of a chlorinating agent into a
compound of formula (III) 12
[0131] the compound of formula (III), optionally provided with an
amino protective group, is reacted with an optionally substituted
compound selected from among the following formulae (IV), which may
be mono- or polysubstituted by R.sup.10, 13
[0132] wherein X, Y, Z, R.sup.9 and R.sup.10 may have the meanings
given hereinbefore, and the product of formula (V) 14
[0133] wherein R.sup.2, R.sup.3 and R.sup.4 may have the meanings
given hereinbefore, is reacted with a compound of formula (VIa) or
(VIb) 15
[0134] where R.sup.1, R.sup.5, R.sup.6 and R.sup.7 may have the
meanings given hereinbefore,
[0135] while preferably R.sup.8 denotes hydrogen or optionally
substituted C.sub.1-C.sub.10-alkyl and preferably R.sup.9 denotes
hydrogen or a group selected from among optionally substituted
C.sub.1-C.sub.10-alkyl, C.sub.3-C.sub.8-cycloalkyl, heterocyclyl,
aryl and heteroaryl.
[0136] The term alkyl groups, including alkyl groups which are a
part of other groups, denotes branched and unbranched alkyl groups
with 1 to 10 carbon atoms, while groups with 1 to 6 carbon atoms
are preferred. Particularly preferred are alkyl groups with 1 to 4
carbon atoms, particularly those with 1 or 2 carbon atoms. Examples
include: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl,
octyl, nonyl and decyl. Unless otherwise stated, the
above-mentioned terms propyl, butyl, pentyl, hexyl, heptyl, octyl,
nonyl and decyl include all the possible isomeric forms. For
example, the term propyl includes the two isomeric groups n-propyl
and iso-propyl, the term butyl includes n-butyl, iso-butyl, sec.
butyl and tert.-butyl, the term pentyl includes iso-pentyl,
neopentyl, etc.
[0137] In the above-mentioned alkyl groups one or more hydrogen
atoms may optionally be replaced by other groups. For example,
these alkyl groups may be substituted by the halogen atoms
fluorine, chlorine, bromine or iodine. Preferably the substituents
are fluorine or chlorine. The substituent chlorine is most
preferred. All the hydrogen atoms of the alkyl group may optionally
also be replaced.
[0138] Similarly, in the above-mentioned alkyl groups, unless
otherwise stated, one or more hydrogen atoms may optionally be
replaced, for example, by OH, NO.sub.2, CN or an optionally
substituted group selected from among --O--C.sub.1-C.sub.5-alkyl,
preferably methoxy or ethoxy, --O--(C.sub.6-C.sub.14-aryl),
preferably phenyloxy, --O-heteroaryl, preferably --O-thienyl,
--O-thiazolyl, --O-imidazolyl, --O-pyridyl, --O-pyrimidyl or
--O-pyrazinyl, saturated or unsaturated --O-heterocycloalkyl,
preferably --O-pyrazolyl, --O-pyrrolidinyl, --O-piperidinyl,
--O-piperazinyl or --O-tetrahydro-oxazinyl, C.sub.6-C.sub.14-aryl,
preferably phenyl, heteroaryl, preferably thienyl, thiazolyl,
imidazolyl, pyridyl, pyrimidyl or pyrazinyl, saturated or
unsaturated heterocycloalkyl, preferably pyrazolyl, pyrrolidinyl,
piperidinyl, piperazinyl or tetrahydro-oxazinyl, an amine group,
preferably methylamine, benzylamine, phenylamine or
heteroarylamine, saturated or unsaturated bicyclic ring systems,
preferably benzimidazolyl and C.sub.3-C.sub.8-cycloalkyl,
preferably cyclohexyl or cyclopropyl.
[0139] Alkenyl groups as well as alkenyl groups which are a part of
other groups denote branched and unbranched alkyl groups with 1 to
10 carbon atoms, preferably 1 to 6, particularly preferably 1 to 4
carbon atoms, which contain at least one carbon-carbon double bond.
Examples include: ethenyl, propenyl, methylpropenyl, butenyl,
pentenyl, hexenyl, heptenyl, methylheptenyl, octenyl, nonenyl and
decenyl. Unless stated otherwise, the terms propenyl, butenyl,
pentenyl, hexenyl, heptenyl, octenyl, nonenyl and decenyl used
above include all the possible isomeric forms. For example, the
term butenyl includes the isomeric groups but-1-enyl, but-2-enyl
and but-3-enyl, etc.
[0140] In the above-mentioned alkenyl groups one or more hydrogen
atoms may optionally be replaced by other groups. For example,
these alkenyl groups may be substituted by the halogen atoms
fluorine, chlorine, bromine or iodine. The substituents fluorine or
chlorine are preferred. The substituent fluorine is particularly
preferred. It is also possible to replace all the hydrogen atoms of
the alkenyl group.
[0141] Alkynyl groups as well as alkynyl groups which are a part of
other groups denote branched and unbranched alkyl groups with 1 to
10 carbon atoms, preferably 1 to 6, particularly preferably 1 to 4
carbon atoms which contain at least one carbon-carbon triple bond.
Examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl,
heptynyl, octynyl, nonynyl and decynyl. Unless otherwise mentioned,
the terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl,
nonynyl and decynyl used above include all the possible isomeric
forms. For example, the term butynyl includes the isomeric groups
but-1-ynyl, but-2-ynyl and but-3-ynyl, etc. In the above-mentioned
alkynyl groups one or more hydrogen atoms may optionally be
replaced by other groups. For example, these alkynyl groups may be
substituted by the halogen atoms fluorine, chlorine, bromine or
iodine. The substituents fluorine or chlorine are preferred. The
substituent fluorine is particularly preferred. It is also possible
to replace all the hydrogen atoms of the alkynyl group.
[0142] The term aryl denotes an aromatic ring system with 6 to 18
carbon atoms, preferably 6 to 14 carbon atoms, preferably 6 or 10
carbon atoms, most preferably phenyl, which may optionally be
substituted and may preferably carry one or more of the following
substituents: OH, NO.sub.2, CN, --OCHF.sub.2, --OCF.sub.3,
--NH.sub.2, --NH-alkyl, --N(alkyl)-alkyl, --NH-aryl,
--N(alkyl)-aryl, --NHCO-alkyl, --NHCO-aryl, --N(alkyl)-CO-alkyl,
--N (alkyl)-CO-aryl, --NHSO.sub.2-alkyl,
--NHSO.sub.2--N(alkyl).sub.2, --NHSO.sub.2-aryl,
--N(alkyl)-SO.sub.2-alky- l, --N (alkyl)-SO.sub.2-aryl,
--CO.sub.2-alkyl, --SO.sub.2-alkyl, --SO.sub.2-aryl, --CON H(OH),
--CONH-alkyl, --CONH-aryl, --CON(alkyl)-alkyl, --CON(alkyl)-aryl,
--SO.sub.2NH-alkyl, --SO.sub.2N H-aryl, --SO.sub.2N(alkyl)-alkyl,
--SO.sub.2N(alkyl)-aryl, --O-alkyl, --O-aryl --S-alkyl, --S-aryl,
tetrazolyl, halogen, for example fluorine, chlorine, bromine or
iodine, preferably fluorine or chlorine, particularly fluorine,
C.sub.1-C.sub.10-alkyl, preferably C.sub.1-C.sub.5-alkyl,
particularly preferably C.sub.1-C.sub.3-alkyl, most particularly
preferably methyl or ethyl, --O--(C.sub.1-C.sub.3-alkyl- ),
preferably methoxy or ethoxy, --COOH or --CONH.sub.2.
[0143] Examples of heteroaryl groups are 5 to 10-membered mono- or
bicyclic heteroaryl rings wherein up to three C atoms may be
replaced by one heteroatoms selected from among oxygen, nitrogen or
sulphur, for example furan, thiophene, pyrrole, pyrazole,
imidazole, triazole, tetrazole, pyridine, pyridazine, pyrimidine,
pyrazine, triazine, oxazole, isoxazole, thiazole, thiadiazole,
oxadiazole, while each of the above-mentioned heterocycles may
optionally also be annellated to a benzene ring, such as
benzimidazole, and these heterocycles may optionally be substituted
and preferably carry one or more of the following substituents: OH,
NO.sub.2, CN, --NH.sub.2, --NH-alkyl, --N(alkyl)-alkyl, --NH-aryl,
--N(alkyl)-aryl, --NHCO-alkyl, --NHCO-aryl, --N(alkyl)-CO-alkyl,
--N(alkyl)-CO-aryl, --NHSO.sub.2-alkyl, --NHSO.sub.2-aryl,
--N(alkyl)-SO.sub.2-alkyl, --N(alkyl)-SO.sub.2-aryl,
--CO.sub.2-alkyl, --SO.sub.2-alkyl, --SO.sub.2-aryl, --CONH-alkyl,
--CONH-aryl, --CON(alkyl)-alkyl, --CON(alkyl)-aryl,
--SO.sub.2NH-alkyl, --SO.sub.2NH-aryl, --SO.sub.2N(alkyl)-alkyl,
--SO.sub.2N(alkyl)-aryl, --O-alkyl, --O-aryl --S-alkyl, --S-aryl,
--CONH.sub.2, halogen, preferably fluorine or chlorine,
C.sub.1-C.sub.10-alkyl, preferably C.sub.1-C.sub.5-alkyl,
preferably C.sub.1-C.sub.3-alkyl, particularly preferably methyl or
ethyl, --O--(C.sub.1-C.sub.3-alkyl), preferably methoxy or ethoxy,
--COOH, --COOCH.sub.3, --CONH.sub.2, --SO-alkyl, --SO.sub.2-alkyl,
--SO.sub.2H, --SO.sub.3-alkyl or optionally substituted phenyl.
[0144] Examples of cycloalkyl groups are saturated or unsaturated
cycloalkyl groups with 3 to 8 carbon atoms, for example
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl or cyclooctyl, preferably cyclopropyl,
cyclopentyl or cyclohexyl, while each of the above-mentioned
cycloalkyl groups may optionally also carry one or more
substituents or be annellated to a benzene ring.
[0145] Unless otherwise stated in the definitions, examples of
heterocycloalkyl or heterocyclyl groups include 5-, 6- or
7-membered, saturated or unsaturated heterocycles which may contain
nitrogen, oxygen or sulphur as heteroatoms, for example
tetrahydrofuran, tetrahydrofuranone, .gamma.-butyrolactone,
.alpha.-pyran, .gamma.-pyran, dioxolane, tetrahydropyran, dioxane,
dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine,
pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole,
piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine,
tetrazine, morpholine, thiomorpholine, diazepan, oxazine,
tetrahydro-oxazinyl, isothiazole and pyrazolidine, preferably
pyrazolyl, pyrrolidinyl, piperidinyl, piperazinyl or
tetrahydro-oxazinyl, while the heterocyclic group may optionally be
substituted.
[0146] The compounds of the above general formula (I) which contain
a group that can be cleaved in-vivo are so-called prodrugs, and
compounds of general formula I which contain two groups that can be
cleaved in-vivo are so-called double prodrugs.
[0147] By a group which can be converted in-vivo into a carboxy
group is meant for example an ester of formula --CO.sub.2R.sup.11,
where
[0148] R.sup.11 denotes hydroxymethyl, alkenyl, alkynyl, aryl,
heteroaryl, cycloalkenyl, heterocycloalkyl,
C.sub.1-C.sub.3-alkoxycarbonyl,
1,3-dihydro-3-oxo-1-isobenzofuranol,
--C(-alkyl)(-alkyl)-OC(O)-alkyl, --CHC(O)NH(-alkyl),
--CHC(O)N(-alkyl)(-alkyl), -alkyl, preferably
C.sub.1-C.sub.6-alkyl, particularly preferably methyl, ethyl,
n-propyl, iso-propyl, n-butyl, n-pentyl or n-hexyl, cycloalkyl,
preferably C.sub.1-C.sub.6-cycloalkyl, particularly preferably
cyclohexyl, --(C.sub.1-C.sub.3-alkyl)-aryl, preferably
(C.sub.1-C.sub.3-alkyl)-phenyl- , particularly preferably benzyl,
--CHC(O)N(-alkyl)(-alkyl), preferably
--CHC(O)N(--C.sub.1-C.sub.3-alkyl)(--C.sub.1-C.sub.3-alkyl),
particularly preferably --CHC(O)N(CH.sub.3).sub.2,
--CH(-alkyl)OC(O)-alkyl, preferably
--CH(--CH.sub.3)OC(O)(--C.sub.1-C.sub.6-alkyl), particularly
preferably --CH(--CH.sub.3)OC(O)-methyl,
--CH(--CH.sub.3)OC(O)-ethyl, --CH(--CH.sub.3)OC(O)-n-propyl,
--CH(--CH.sub.3)OC(O)-n-butyl or --CH(--CH.sub.3)OC(O)-t-butyl, or
--CH.sub.2OC(O)-alkyl, preferably
--CH.sub.2OC(O)(--C.sub.1-C.sub.6-alkyl), particularly preferably
--CH.sub.2OC(O)-methyl, --CH.sub.2OC(O)-ethyl,
--CH.sub.2OC(O)-n-propyl, --CH.sub.2OC(O)-n-butyl or
--CH.sub.2OC(O)-t-butyl.
[0149] By a group which can be converted in-vivo into a
sulphonamide or amino group is meant for example one of the
following groups:
[0150] --OH, -formyl, --C(O)-alkyl, --C(O)-aryl, --C(O)-heteroaryl,
--CH.sub.2OC(O)-alkyl, --CH(-alkyl)OC(O)-alkyl,
--C(-alkyl)(-alkyl)OC(O)-- alkyl, --CO.sub.2-alkyl, preferably
C.sub.1-C.sub.9-alkoxy-carbonyl, particularly preferably
methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl,
isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxycarbonyl,
n-hexyloxycarbonyl, cyclohexyloxycarbonyl, n-heptyloxycarbonyl,
n-octyloxycarbonyl or n-nonyloxycarbonyl,
--CO.sub.2(--C.sub.1-C.sub.3-alkyl)-aryl, preferably
--CO.sub.2(--C.sub.1-C.sub.3-alkyl)-phenyl, particularly preferably
benzyloxycarbonyl, --C(O)-aryl, preferably benzoyl,
--C(O)-heteroaryl, preferably pyridinoyl or nicotinoyl or
--C(O)-alkyl, preferably --C(O)(--C.sub.1-C.sub.6-alkyl),
particularly preferably 2-methyl-sulphonylethoxycarbonyl-,
2-(2-ethoxy)-ethoxycarbonyl-.
[0151] Halogen generally denotes fluorine, chlorine, bromine or
iodine, preferably chlorine or fluorine, particularly preferably
fluorine.
[0152] The compounds according to the invention may be in the form
of the individual optical isomers, mixtures of the individual
enantiomers, diastereomers or racemates, prodrugs, double prodrugs
and in the form of the tautomers, salts, solvates and hydrates as
well as in the form of the free bases or the corresponding acid
addition salts with pharmacologically acceptable acids--such as for
example acid addition salts with hydrohalic acids, for example
hydrochloric or hydrobromic acid, or organic acids, such as for
example oxalic, fumaric, diglycolic, formic, malic, benzoic,
benzenesulphonic, camphorsulphonic, acetic, ethanesulphonic,
glutamic, maleic, mandelic, lactic, phosphoric, nitric, sulphuric,
succinic, para-toluenesulphonic, trifluoroacetic, tartaric, citric
or methanesulphonic acid.
[0153] Moreover, if the new compounds of formula I thus obtained
contain a carboxy group or another acid group, they may
subsequently, if desired, be converted into the salts thereof with
inorganic or organic bases, particularly for pharmaceutical use
into the physiologically acceptable salts thereof. Suitable bases
for this purpose include for example sodium hydroxide, potassium
hydroxide, cyclohexylamine, ethanolamine, diethanolamine and
triethanolamine.
[0154] Moreover the compounds of general formula I obtained may be
resolved into their enantiomers and/or diastereomers.
[0155] Thus, for example, the compounds of general formula I
obtained which occur as racemates may be separated by methods known
per se (cf. Allinger N. L. and Eliel E. L. in "Topics in
Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their
optical antipodes and compounds of general formula I with at least
2 asymmetric carbon atoms may be resolved into their diastereomers
on the basis of their physical-chemical differences using methods
known per se, e.g. by chromatography and/or fractional
crystallisation, and, if these compounds are obtained in racemic
form, they may subsequently be resolved into the enantiomers as
mentioned above.
[0156] The enantiomers are preferably separated by column
separation on chiral phases or by recrystallisation from an
optically active solvent or by reacting with an optically active
substance which forms salts or derivatives such as e.g. esters or
amides with the racemic compound, particularly acids and the
activated derivatives or alcohols thereof, and separating the
diastereomeric mixture of salts or derivatives thus obtained, e.g.
on the basis of their differences in solubility, whilst the free
antipodes may be released from the pure diastereomeric salts or
derivatives by the action of suitable agents. Optically active
acids in common use are e.g. the D- and L-forms of tartaric acid or
dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid,
mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid
or quinic acid. An optically active alcohol may be, for example,
(+) or (-)-menthol and an optically active acyl group in amides,
for example, may be a (+)- or (-)-menthyloxycarbonyl.
[0157] The substituent R.sup.1 may represent optionally substituted
aryl or heteroaryl, preferably substituted phenyl. Particularly
preferably, the substituent R.sup.1 denotes phenyl.
[0158] The substituent R.sup.2 may represent a heteroaryl or
heterocyclyl mono- or polysubstituted by R.sup.10, where R.sup.2
contains at least one nitrogen atom. Particularly preferred is a
triazole mono- or polysubstituted by R.sup.10, a
1,4-dioxo-3,4-dihydro-1H-phthalazine mono- or polysubstituted by
R.sup.10, a 2-oxoimidazolidine mono- or polysubstituted by
R.sup.10, a benzimidazole mono- or polysubstituted by R.sup.10 or
an imidazole mono- or polysubstituted by R.sup.10.
[0159] Most particularly preferred meanings of the substituent
R.sup.2 are a 1H-[1,2,3]triazol-1-yl monosubstituted by R.sup.10, a
1,4-dioxo-3,4-dihydro-1H-phthalazin-2-yl monosubstituted by
R.sup.10, a 2-oxo-imidazolidin-1-yl monosubstituted by R.sup.10, a
benzimidazol-1-yl monosubstituted by R.sup.10 or an imidazol-1-yl
monosubstituted by R.sup.10.
[0160] The substituents R.sup.3 and R.sup.4 may independently of
one another represent hydrogen or an optionally substituted group
selected from among C.sub.3-C.sub.6-cycloalkyl or
C.sub.1-C.sub.5-alkyl, preferably C.sub.1-C.sub.5-alkyl, or R.sup.3
and R.sup.4 together represent a 2- to 7-membered alkylene bridge,
preferably a 2- to 5-membered alkylene bridge, particularly an
ethylene bridge.
[0161] A substituted R.sup.3 or R.sup.4 is preferably substituted
by C.sub.1-C.sub.3-alkyl.
[0162] Preferably R.sup.3 denotes methyl.
[0163] Preferably R.sup.4 denotes methyl.
[0164] The substituents R.sup.5, R.sup.6 and R.sup.7 may
independently of one another denote hydrogen or a group selected
from among halogen, cyano, --NR.sup.8CO--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8CO-aryl, --NR.sup.8SO.sub.2--(C.sub.1-C.sub.5-alkyl),
--NR.sup.8SO.sub.2-aryl, --CO.sub.2R.sup.8, --SO.sub.2R.sup.8,
--CONHR.sup.8, --SO.sub.2NHR.sup.8, --OR.sup.8, optionally
substituted C.sub.3-C.sub.6-cycloalkyl and optionally substituted
C.sub.1-C.sub.10-alkyl, preferably hydrogen, halogen, cyano,
methoxy, methanesulphonylamino, methanesulphonyl, difluoromethoxy,
trifluoromethoxy, difluoromethyl or trifluoromethyl, particularly
hydrogen, fluorine, chlorine or cyano. A most particularly
preferred definition of the substituents R.sup.5, R.sup.6 and
R.sup.7 is hydrogen.
[0165] The substituent R.sup.8 may represent hydrogen or
C.sub.1-C.sub.5-alkyl, preferably methyl.
[0166] The substituent R.sup.9 may represent hydrogen, optionally
substituted aryl or optionally substituted heteroaryl, preferably
optionally substituted phenyl, pyridyl or thiophenyl.
[0167] The substituent R.sup.10 may represent OH, NO.sub.2, CN,
--OCHF.sub.2, --OCF.sub.3, --NH.sub.2, --NH-alkyl,
--N(-alkyl)-alkyl, --NH-aryl, --N(-alkyl)-aryl, --NHCO-alkyl,
--NHCO-aryl, --N(-alkyl)CO-alkyl, --N(-alkyl)CO-aryl,
--NHSO.sub.2-alkyl, --NHSO.sub.2-aryl, --N(-alkyl)SO.sub.2-alkyl,
--N(-alkyl)-SO.sub.2-aryl, --CO.sub.2-alkyl, --SO.sub.2-alkyl,
--SO.sub.2-aryl, --CONH-alkyl, --CONH-aryl, --CON(-alkyl)-alkyl,
--CON(-alkyl)-aryl, --SO.sub.2NH-alkyl, --SO.sub.2NH-aryl,
--SO.sub.2N(-alkyl)-alkyl, --SO.sub.2N(-alkyl)-aryl, --O-alkyl,
--O-aryl, --S-alkyl, --S-aryl, halogen, C.sub.1-C.sub.10-alkyl,
--O--(C.sub.1-C.sub.3-alkyl), --COOH, --CONH.sub.2,
--CON(-alkyl)SO.sub.2-alkyl, --CONHSO.sub.2-alkyl, --CONHOH,
2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl,
2,5-dihydro-2-oxo-3H-1,2,4,5-- oxathiadiazol-4-yl, tetrazolyl,
heterocyclyl, aryl or heteroaryl.
[0168] Preferably R.sup.10 denotes --OH, --NO.sub.2, --CN,
--NH.sub.2, --I, --N(CH.sub.3).sub.2, --NHCO.sub.2CH.sub.3,
--NHSO.sub.2CH.sub.3, --SO.sub.2N(C H.sub.3).sub.2, --CO.sub.2H,
benzyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, --CONHOH,
tetrazol-5-yl, pyridin-4-yl, pyridin-2-yl, 6-methoxy-pyridin-3-yl,
phenyl, 4-hydroxyphenyl, 4-fluorophenyl, 4-methoxy-phenyl,
4-aminophenyl, 4-nitrophenyl, thiophen-2-yl,
5-methyl-thiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl or
1-acetyl-2-amino-propenyl.
[0169] The compounds according to the invention may be prepared by
the methods of synthesis described below, while formulae (I) to
(VI) and the substituents of general formulae R.sup.1 to R.sup.7
have the meanings given hereinbefore. These methods are intended as
an illustration of the invention without restricting it to their
content. 16
[0170] General Methods of Synthesis
Synthesis of the 3-chloropropylamine-hydrochlorides
[0171] 17
[0172] 130 mmol thionyl chloride were slowly added dropwise at
0.degree. C. to a solution of 100 mmol 3-aminobutanol in 50 mL
methylene chloride/dimethylformamide (50:1) with vigorous stirring.
After the addition had ended the reaction mixture was refluxed for
about 1 hour (h) at reflux temperature and then stirred for about
16 h at ambient temperature. The solvent was removed and the
residue was combined with 10 mL acetonitrile with stirring. The
solid was filtered off and dried.
Synthesis of the tert-butyl (3-chloropropyl)-carbamates
[0173] 18
[0174] 100 mmol di-tert.-butyldicarbonate were added batchwise to a
solution of 140 mmol 3-chloropropylamine hydrochloride and 330 mmol
triethylamine in 400 mL methylene chloride at ambient temperature
with vigorous stirring. After the addition had ended the reaction
mixture was stirred for about 4 days (d) at ambient temperature
(RT). The solvent was removed and the residue was taken up in about
100 mL ethyl acetate and about 200 mL water. The phases were
separated and the aqueous phase was extracted twice with about 100
mL ethyl acetate. The combined organic phases were washed about
three times with 100 mL water, dried over sodium sulphate and the
solvent was eliminated using the rotary evaporator.
Synthesis of the substituted tert-butyl
(3-aminopropyl)-carbamates
[0175] 19
[0176] 11 mmol sodium hydride were added batchwise at 5.degree. C.
to a solution of 10 mmol HR.sup.2 in 15 mL of
1,3-dimethyl-3,4,5,6-tetrahydro-- 2 (1H)-pyrimidone, with vigorous
stirring. After the development of gas had ended the reaction
mixture was stirred for about 1 h at 0.degree. C. and 10 mmol
tert-butyl (3-chloropropyl)-carbamate in 5 mL
1,3-dimethyl-3,4,5,6-tetrahydro-2 (1H)-pyrimidone and 1 mmol
tetrabutylammonium iodide were added. The reaction mixture was
stirred for approx. 48 h at ambient temperature and then poured
into 450 mL ice water/ethyl acetate 2:1. The phases were separated
and the aqueous phase was extracted about three times with 100 mL
ethyl acetate. The combined organic phases were washed about five
times with 100 mL water, then with about 100 mL saturated, aqueous
sodium chloride solution, dried and freed from the solvent. The
residue was purified by flash column chromatography.
Synthesis of the Substituted Amines
[0177] 20
[0178] 2 mL trifluoroacetic acid were added to a solution of 1
mmol) tert-butyl
{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimethyl--
propyl}-carbamate in 5 mL dichloromethane at ambient temperature
with vigorous stirring. The reaction mixture was stirred for
approx. 16 h at ambient temperature and then freed from the
solvent. The residue was stirred with diethyl ether or purified by
flash column chromatography.
[0179] The free base was prepared from the
amine-bistrifluoroacetate obtained using known methods.
Synthesis Route A):
Synthesis of the substituted 2-chloro-1-phenylethanones
[0180] 21
[0181] 30 mmol sulphuryl chloride were added dropwise with vigorous
stirring to a solution of 10 mmol 1-phenylethanone in about 50 mL
dichloromethane at 0.degree. C. over approx. 30 min. The reaction
mixture was refluxed for approx. 3 h, cooled to ambient temperature
and washed with about 50 mL water, about 50 mL saturated, aqueous
sodium hydrogen carbonate solution and about 50 mL saturated
aqueous sodium chloride solution. The organic phase was dried and
freed from the solvent.
Synthesis of the substituted 2-chloro-1-phenyl-ethanols
[0182] 22
[0183] 11 mmol borane-tetrahydrofuran complex (1M in
tetrahydrofuran) were added dropwise at 10.degree. C. with vigorous
stirring over approx. 30 min to a solution of 10 mmol
2-chloro-1-phenylethanone in about 25 mL tetrahydrofuran. After the
development of gas had ended the reaction was stirred for approx.
16 h at ambient temperature and then poured into about 450 mL
water/ethyl acetate 2:1. The phases were separated and the aqueous
phase was extracted about three times with 100 mL ethyl acetate.
The combined organic phases were washed about twice with 100 mL
water, then with about 100 mL saturated, aqueous sodium chloride
solution, dried and freed from the solvent. The residue was
purified by flash column chromatography
[0184] By using an enantioselective reducing agent (Shinichi, I.,
Organic Reactions 1998, 52, 395-576; Wallabaum, S.; Martens, J.
Tetrahedron: Asymmetry 1992, 3, 1475-1504; Hett, R.; Senanayake, C.
H.; Wald, S. A. Tetrahedron Letters 1998, 39, 1705-1708; Yaozhong,
J.; Yong, Q.; Aiqiao, M.; Zhitang, M. Tetrahedron: Asymmetry 1994,
5, 1211-1214; Sawa, I.; Konishi, Y.; Maemoto, S.; Hasegawa, J. WO
9201804A1, 1992; Yasohara, Y.; Sawa, I.; Ueda, M.; Hasegawa, J.;
Shimizu, A.; Kataoka, M.; Wada M.; Kawabata, J. JP 11215995, 1999;
Hamada, T.; Torii, T.; Izawa, K.; Noyori, R.; Ikariya, T. Organic
Letters 2002, 4, 4373-4376) the 2-chloro-1-phenylethanols may also
be obtained in enantiomerically pure form. The (R)-enantiomers are
of outstanding importance according to the invention.
Synthesis of the Substituted Phenyloxirans
[0185] 23
[0186] 13 mmol potassium carbonate and 2 mmol sodium iodide were
added to a solution of 10 mmol 2-chloro-1-phenylethanol in about 30
mL acetonitrile. The reaction mixture was refluxed for approx. 8 h
and then poured into about 150 mL water/ethyl acetate 2:1. The
phases were separated and the aqueous phase was extracted about
three times with 50 mL ethyl acetate. The combined organic phases
were washed with about 50 mL water, then with about 50 mL
saturated, aqueous sodium chloride solution, dried and freed from
the solvent. The residue was purified by flash column
chromatography.
Synthesis of the Substituted Phenyloxiran (R)-enantiomers
[0187] 24
[0188] Carried out analogously to a process described in the
literature (Org. Lett. 2002, 4, 4373-4376).
[0189] 6 mL of a mixture of formic acid and triethylamine (molar
ratio=5:2) are added dropwise at 0.degree. C. to a solution of 30
mmol of a substituted 2-chloro-1-phenylethanone and 0.03 mmol
Cp*RhCl[(S,S)-TsDPEN] (Cp*=pentamethylcyclopentadienyl and
TsDPEN=(1S,2S)-N-p-toluenesulphonyl-1,2-diphenylethylenediamine) in
15 mL dimethylformamide. The mixture is stirred for 24 h at
0.degree. C. and 45 mg catalyst and 6 mL of a mixture of formic
acid and triethylamine (molar ratio=5:2) are added thereto. After
another 2.5 h stirring at 0.degree. C. the reaction mixture is
combined at 0.degree. C. with 33.9 mL sodium hydroxide solution.
The reaction mixture is stirred for 1.5 h at 0.degree. C.,
acidified with 13.5 mL glacial acetic acid and extracted about
three times with ethyl acetate. The combined organic phases were
washed about three times with water and then with saturated,
aqueous sodium chloride solution, dried over sodium sulphate and
freed from the solvent. The residue was purified by flash column
chromatography.
[0190] The further reactions are carried out analogously in each
case: starting from racemic educts racemic products are obtained
and starting from enantiomerically pure compounds enantiomerically
pure products are obtained. Alternatively, a racemic end compound
obtained may be separated into the two enantiomers for example by
chiral column chromatography or by recrystallisation with suitable
chiral counter-ions.
Synthesis of the Substituted Ethanolamines
[0191] 25
[0192] 1 mmol phenyloxiran was added to a solution of 1 mmol amine
in 2 mL ethanol and refluxed for approx. 18 h. The reaction mixture
was freed from the solvent and the residue was purified by flash
column chromatography or recrystallisation. The free ethanolamine
or the corresponding salt was obtained as a solid.
Synthesis Route B):
Synthesis of the Substituted Ethoxy-Hydroxyketones
[0193] 26
[0194] 5 ml of water, 5 g activated charcoal and 60 mmol selenium
dioxide were added to a solution of 30 mmol 1-phenylethanone in
about 50 mL dioxane. The reaction mixture was stirred for approx.
20 h at 80.degree. C. and then the solvent was eliminated using the
rotary evaporator. The residue was dissolved in about 30 ml of
ethanol and refluxed for approx. 6 h. The reaction mixture was
freed from the solvent, dissolved in about 150 mL ethyl acetate,
washed about three times with 100 ml saturated, aqueous sodium
hydrogen carbonate solution, dried and the solvent was eliminated
using the rotary evaporator. The residue was purified by flash
column chromatography.
Synthesis of the Substituted Ethanolamines
[0195] 27
[0196] 1 mmol ethoxy-hydroxyketone was added to 1 mmol amine
bistrifluoroacetate in 10 mL ethanol and refluxed for approx. 18 h.
The reaction mixture was cooled to 0.degree. C. and then combined
with 3 mmol sodium borohydride. It was stirred for approximately
another 3 h at ambient temperature and then combined with 20 mL
saturated, aqueous potassium carbonate solution and 20 mL ethyl
acetate. The phases were separated and the aqueous phase was
extracted with ethyl acetate. The combined organic phases were
washed with saturated, aqueous sodium chloride solution, dried and
freed from the solvent. The residue was purified by flash column
chromatography or recrystallisation. The free ethanolamine or the
corresponding salt was thus obtained as a solid.
[0197] Suzuki Coupling of Substituted Iodoimidazoles with
Substituted Boric Acids
[0198] 1 mmol iodoimidazole, 2 mmol arylboric acid, 0.01 mmol
tetrakis(triphenylphosphino)palladium and 0.01 mmol
tetrabutylammonium bromide in 20 mL saturated aqueous sodium
hydrogen carbonate solution/toluene (1:1) were refluxed for approx.
3 d. The reaction mixture was combined at ambient temperature with
about 100 mL toluene water (1:1), the phases were separated and the
organic phase was washed about three times with 50 mL water. The
organic phase was dried and freed from the solvent. The residue was
purified by flash column chromatography. The desired
phenylimidazole was obtained as a colourless oil.
[0199] The new compounds of general formula (I) may be synthesised
analogously to the following examples of synthesis. These Examples
are intended purely as a further illustration of the invention
without restricting it to their content.
EXAMPLE 22
Synthesis of
N-[3-(2-ethoxy-2-hydroxyacetyl)-phenyl]-benzenesulphonamide
[0200] 28
[0201] 1 ml of water, 1 g activated charcoal and 2.66 g (24 mmol)
selenium dioxide was added to a solution of 1.65 g (6.00 mmol)
N-(acetylphenyl)benzenesulphonamide in about 10 mL dioxane. The
reaction mixture was stirred for approx. 4 d at 80.degree. C. and
then the solvent was eliminated using the rotary evaporator. The
residue was dissolved in about 30 ml of ethanol and refluxed for
approx. 4 h. The solvent was eliminated from the reaction mixture
using the rotary evaporator, the residue was dissolved in about 100
mL ethyl acetate, washed about three times with 30 ml saturated
aqueous sodium hydrogen carbonate solution, dried over sodium
sulphate and the solvent was eliminated using the rotary
evaporator. 0.917 g (2.73 mmol, 46%) N-[3-(2-ethoxy-2-hydroxyacety-
l)-phenyl]-benzenesulphonamide were obtained as a yellow solid.
Synthesis of 3-chloro-1,1-dimethylpropylamine-hydrochloride
[0202] 29
[0203] 48.7 mL (668 mmol) thionyl chloride were slowly added
dropwise at 0.degree. C. with vigorous stirring to a solution of
53.0 g (514 mmol) 3-amino-3-methyl-butanol in 255 mL methylene
chloride/dimethylformamide (50:1). After the addition had ended the
reaction mixture was refluxed for 1 h at reflux temperature and
then stirred for 16 h at ambient temperature. The solvent was
removed and the residue was combined with 50 mL acetonitrile with
stirring. The solid was filtered off and dried for 18 h at
45.degree. C. 67.9 g (430 mmol, 84%) 3-chloro-1,1-dimethylpropyla-
mine-hydrochloride were obtained as a colourless solid.
Synthesis of tert-butyl
(3-chloro-1,1-dimethyl-propyl)-carbamate
[0204] 30
[0205] 101 g (218 mmol) di-tert.-butyldicarbonate were added
batchwise to a solution of 48.8 g (309 mmol)
3-chloro-1,1-dimethylpropylamine-hydrochl- oride and 100 mL (718
mmol) triethylamine in 900 mL methylene chloride, at ambient
temperature, with vigorous stirring. After the addition had ended
the reaction was stirred for 4 d at RT. The solvent was removed and
the residue was taken up in 250 mL ethyl acetate and 400 mL water.
The phases were separated and the aqueous phase was extracted twice
with 200 mL ethyl acetate. The combined organic phases were washed
three times with 150 mL water, dried over sodium sulphate and the
solvent was eliminated using the rotary evaporator. 45.3 g (204
mmol, 66%) tert-butyl (3-chloro-1,1-dimethyl-propyl)-carbamate were
obtained as a colourless oil.
Synthesis of tert-butyl
[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propyl]-car- bamate
[0206] 31
[0207] 0.556 g (22.0 mmol) sodium hydride were added batchwise to a
solution of 3.88 g (20.0 mmol) iodoimidazole in 30 mL
1,3-dimethyl-3,4,5,6-tetrahydro-2 (1H)-pyrimidone at 5.degree. C.
with vigorous stirring. After the development of gas had ended the
reaction was stirred for 1 h at 0.degree. C. and 4.44 g (20 mmol)
tert-butyl (3-chloro-1,1-dimethyl-propyl)-carbamate in 5 mL
1,3-dimethyl-3,4,5,6-tet- rahydro-2 (1H)-pyrimidone and 0.739 g
(2.00 mmol) tetrabutylammonium iodide were added. The reaction
mixture was stirred for 16 h at ambient temperature, stirred for 24
h at 80.degree. C., cooled to ambient temperature and poured into
750 mL ice water/ethyl acetate 2:1. The phases were separated and
the aqueous phase was extracted three times with 150 mL ethyl
acetate. The combined organic phases were washed five times with
150 mL water, then once with 150 mL saturated, aqueous sodium
chloride solution, dried over sodium sulphate and the solvent was
eliminated using the rotary evaporator. The residue was purified by
flash column chromatography [petroleum ether/ethyl acetate
(80:20->0:100)]. 3.19 g (8.40 mmol, 42%) tert-butyl
[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl- -propyl]-carbamate were
obtained as a colourless oil.
Synthesis of 3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propylamine
[0208] 32
[0209] 10 mL (130 mmol) trifluoroacetic acid were added to a
solution of 1.90 g (5.00 mmol) tert-butyl
[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-prop- yl]-carbamate in 90 mL
dichloromethane at ambient temperature with vigorous stirring. The
reaction mixture was stirred for 16 h at ambient temperature and
the solvent was eliminated using the rotary evaporator. The residue
was taken up in 100 mL sodium hydroxide solution (1M) and 100 mL
dichloromethane. The phases were separated and the aqueous phase
was extracted three times with 100 mL dichloromethane. The combined
organic phases were dried over magnesium sulphate and the solvent
was eliminated using the rotary evaporator. 1.37 g (4.91 mmol, 98%)
3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propylamine were obtained as
a colourless oil.
Synthesis of
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-prop-
ylamino]-ethyl}-phenyl)-benzenesulphonamide (Example 10)
[0210] 33
[0211] 7.81 g (23.3 mmol)
N-[3-(2-ethoxy-2-hydroxy-acetyl)-phenyl]-benzene- sulphonamide and
6.50 g (23.3 mmol) 3-(4-iodo-imidazol-1-yl)-1,1-dimethyl--
propylamine in 40 mL ethanol were refluxed for 15 h. The reaction
mixture was cooled to 0.degree. C. and then combined with 3.70 g
(97.9 mmol) sodium borohydride. It was stirred for a further 24 h
at ambient temperature stirred and then combined with 20 mL
saturated aqueous potassium carbonate solution. The aqueous phase
was separated from the organic phase and extracted twice with 50 mL
ethyl acetate. The combined organic phases were washed with 20 mL
saturated, aqueous sodium chloride solution, dried over magnesium
sulphate and freed from the solvent using the rotary evaporator.
The residue was purified by flash column chromatography [methylene
chloride/methanol/ammonia (90:10:1)]. 12.9 g (10.5 mmol, 45%)
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-
-propylamino]-ethyl}-phenyl)-benzenesulphonamide were obtained as a
colourless solid.
Synthesis of
N-[3-(2-{1,1-dimethyl-3-[4-(5-methyl-thiophen-2-yl)-imidazol--
1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
(Suzuki coupling)
[0212] 34
[0213] 0.277 g (0.500 mmol)
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,-
1-dimethyl-propylamino]-ethyl}-phenyl)-benzenesulphonamide, 0.807 g
(0.613 mmol) 5-methylthiophene-2-boric acid, 0.031 g (0.038 mmol)
[1,1'-bis(diphenylphosphino)ferrocene]-palladium(II)-chloride (1:1
complex with dichloromethane), 2.00 mL aqueous sodium carbonate
solution (2M) and 2 mL dioxane were stirred for 5 min at
150.degree. C. in a sealed reaction vessel in a microwave. The
reaction mixture was cooled to ambient temperature and then poured
into 20 mL dichloromethane and 20 mL water. The phases were
separated, the organic phase was washed twice with 20 mL water,
dried over magnesium sulphate and the solvent was eliminated using
the rotary evaporator. The residue was purified by flash column
chromatography [methylene chloride/methanol (100:0->75:25)].
0.200 g (0.381 mmol, 76%)
N-[3-(2-{1,1-dimethyl-3-[4-(5-methyl-thiophen-2-yl)-imi-
dazol-1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
were obtained as a beige solid.
[0214] Examples 4, 9, 16, 19, 20, 21, 23, 26, 27, 28 and 38 were
synthesised analogously to the method described for Example 22. In
the last step of the reaction, the following reagents were used
instead of 5-methylthiophene-2-boric acid.
[0215] Example 4: 4-nitrophenylboric acid
[0216] Example 9: 4-methanesulphonylaminoboric acid
[0217] Example 16: 4-benzyloxycarbonylphenylboric acid
[0218] Example 19: 4-acetamidophenylboric acid
[0219] Example 20: 3,5-dimethylisoxazole-4-boric acid
[0220] Example 21: 2-methoxy-5-pyridineboric acid
[0221] Example 23: 4-fluorophenylboric acid
[0222] Example 26: thiophene-2-boric acid
[0223] Example 27: 4-(N,N-dimethylamino)phenylboric acid
[0224] Example 28: 4-ethoxycarbonylphenylboric acid
[0225] Example 38: 4-tetrazolylphenylboric acid (Organic Letters 6
(2004) 19, 3265-3268)
EXAMPLE 14
Synthesis of methyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-eth-
ylamino]-3-methyl-butyl}-1H-imidazole-4-carboxylate (Example
11)
[0226] 35
[0227] 0.554 g (1.00 mmol)
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-
-dimethyl-propylamino]-ethyl}-phenyl)-benzenesulphonamide, 0.055 g
(0,100 mmol) 1,1'-bis-(diphenylphosphino)-ferrocene, 0.022 g (0.100
mmol) palladium(II)acetate and 5 mL methanol were shaken in an
autoclave under a carbon monoxide atmosphere of 2 bar for 15 h at
50.degree. C. The reaction mixture was filtered and the filtrate
was freed from solvent using the rotary evaporator. The residue was
purified by flash column chromatography [methylene
chloride/methanol (100:0->80:20)]. 0.480 g (0.986 mmol, 99%)
methyl 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydro-
xy-ethylamino]-3-methyl-butyl}-1H-imidazole-4-carboxylate were
obtained as a colourless solid.
Synthesis of
1-[3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino-
]-3-methyl-butyl]-1H-imidazole-4-carboxylic acid
[0228] 36
[0229] 4.00 mL sodium hydroxide solution (1M) was added to 7.81 g
(23.3 mmol) methyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamin-
o]-3-methyl-butyl}-1H-imidazole-4-carboxylate in 8 mL
tetrahydrofuran and stirred for 4 h at ambient temperature. The
solvent was eliminated from the reaction mixture using the rotary
evaporator and the residue was combined three times with 20 mL
methanol and filtered. The combined methanolic phases were freed
from solvent using the rotary evaporator and 0.390 g (0.825 mmol,
98%) 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydr-
oxy-ethylamino]-3-methyl-butyl}-1H-imidazole-4-carboxylic acid were
obtained as a colourless solid.
EXAMPLE 5
Synthesis of tert-butyl
{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1-
,1-dimethyl-propyl}-carbamate
[0230] 37
[0231] 0.73 g (60% in oil, 18.3 mmol) sodium hydride were added
batchwise to a solution of 3.69 g (16.6 mmol)
1-(4-fluoro-phenyl)-imidazolidin-2-on- e in 20 mL
1,3-dimethyl-3,4,5,6-tetrahydro-2 (1H)-pyrimidone at 5.degree. C.
with vigorous stirring. After the development of gas had ended the
reaction was stirred for 1 h at 0.degree. C. and 3.00 g (16.6 mmol)
tert-butyl (3-chloro-1,1-dimethyl-propyl)-carbamate and 0.62 g
(1.67 mmol) tetrabutylammonium iodide were added. The reaction
mixture was stirred for 48 h at ambient temperature and then poured
into 500 mL ice water/ethyl acetate 2:1. The phases were separated
and the aqueous phase was extracted three times with 150 mL ethyl
acetate. The combined organic phases were washed five times with
150 mL water, then once with 150 mL saturated, aqueous sodium
chloride solution, dried over sodium sulphate and the solvent was
eliminated using the rotary evaporator. The residue was purified by
flash column chromatography [petroleum ether/ethyl acetate
(70:30)]. 1.35 g (3.69 mmol, 22%) tert-butyl
[{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimethyl-propyl}-ca-
rbamate were obtained as a colourless solid.
Synthesis of
1-(3-amino-3-methyl-butyl)-3-(4-fluoro-phenyl)-imidazolidin-2-
-one
[0232] 38
[0233] 10 mL (130 mmol) trifluoroacetic acid were added to a
solution of 1.35 g (3.9 mmol) tert-butyl
{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-
-yl]-1,1-dimethyl-propyl}-carbamate in 20 mL dichloromethane at
ambient temperature with vigorous stirring. The reaction mixture
was stirred for 16 h at ambient temperature and the solvent was
eliminated using the rotary evaporator. The residue was stirred
with diethyl ether. 1.37 g (4.91 mmol, 98%)
1-(3-amino-3-methyl-butyl)-3-(4-fluoro-phenyl)-imidazoli- din-2-one
bistrifluoroacetate were obtained as a colourless solid.
Synthesis of
N-[3-(2-{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1--
dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0234] 39
[0235] The free base was prepared from 0.34 g (0.90 mmol)
1-(3-amino-3-methyl-butyl)-3-(4-fluoro-phenyl)-imidazolidin-2-one
bistrifluoroacetate by known methods. It was dissolved in 4 mL
ethanol, combined with 0.20 g (0.60 mmol)
N-[3-(2-ethoxy-2-hydroxy-acetyl)-phenyl]- -benzenesulphonamide and
refluxed for 15 h. The reaction mixture was cooled to 0.degree. C.
and then combined with 0.34 g (9.00 mmol) sodium borohydride. It
was stirred for a further 24 h at ambient temperature and then
combined with 20 mL saturated aqueous potassium carbonate solution.
The aqueous phase was separated from the organic phase and
extracted twice with 50 mL ethyl acetate. The combined organic
phases were washed with 20 mL saturated aqueous sodium chloride
solution, dried over magnesium sulphate and freed from the solvent
using the rotary evaporator. The residue was purified by flash
column chromatography [methylene chloride/methanol
(98:2->75:25)]. 0.10 g (0.19 mmol, 31%)
N-[3-(2-{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dimethyl-pro-
pylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide were
obtained as a colourless solid.
[0236] Examples 1, 2, 3, 6, 7, 13, 15, 18, 24, 25, 29, 30, 31 and
37 were synthesised analogously to the method described in Example
5. The following reagents were used in the first reaction step
instead of 1-(4-fluoro-phenyl)-imidazolidin-2-one:
[0237] Example 1: 4-phenylimidazole
[0238] Example 2: 2-methyl-2,3-dihydro-phthalazine-1,4-dione
[0239] Example 3: 4-phenylimidazolidin-2-one
[0240] Example 6: 4-(4-methoxyphenyl)imidazole
[0241] Example 7: 4-(imidazol-4-yl)-phenol
[0242] Example 13: 1-pyridin-2-yl-imidazolidin-2-one
[0243] Example 15: 4-(imidazol-4-yl)-pyridine
[0244] Example 18: 1-(4-hydroxyphenyl)-imidazolidin-2-one
[0245] Example 24: 5-nitrobenzimidazole
[0246] Example 25: 4-(4-methoxyphenyl) [1,2,3]triazole
[0247] Example 29: 4-(4-methoxyphenyl)-imidazolidin-2-one
[0248] Example 30: 4-(4-nitrophenyl)-imidazolidin-2-one
[0249] Example 31: 3-(4-methoxyphenyl) [1,2,4]triazole
[0250] Example 37: ethyl benzimidazole-5-carboxylate
Synthesis of
3-[4-(4-hydroxy-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylami- ne
(the amine component for the last step of the synthesis of Example
7)
[0251] 40
[0252] 1.0 g (4.00 mmol)
3-[4-(4-methoxy-phenyl)-imidazol-1-yl]-1,1-dimeth- yl-propylamine
and 4.00 g pyridine hydrochloride were stirred for 2 h at
200.degree. C. in a sealed reaction vessel in a microwave. The
reaction mixture was poured into 40 mL ice water and 40 mL ethyl
acetate, the pH of the aqueous phase was adjusted to over 9 with
sodium hydroxide solution (2M) and the phases were separated. The
aqueous phase was extracted five times with 50 mL ethyl acetate.
The combined organic phases were dried over magnesium sulphate and
the solvent was eliminated using the rotary evaporator. 0.530 g
(2.16 mmol, 54%)
3-[4-(4-hydroxy-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylamine
were obtained as a colourless solid.
[0253]
1-(3-amino-3-methyl-butyl)-3-(4-hydroxy-phenyl)-imidazolidin-2-one
(amine component for the last step of the synthesis of Example 18)
was synthesised from
1-(3-amino-3-methyl-butyl)-3-(4-methoxy-phenyl)-imidazol-
idin-2-one analogously to the synthesis of
3-[4-(4-hydroxy-phenyl)-imidazo- l-1-yl]-1,1-dimethyl-propylamine
(amine component for the last step of the synthesis of Example
7).
[0254] 1-(3-Amino-3-methyl-butyl)-3-pyridin-2-yl-imidazolidin-2-one
(amine component for the last step of the synthesis of Example 13)
was synthesised analogously to the procedures laid down in
DE2548663 and DE2528078.
EXAMPLE 8
Synthesis of
N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1,1-dimethyl-pr-
opylamino}-1-hydroxyethyl)-phenyl]-benzenesulphonamide
[0255] 41
[0256] 1.69 g (3.07 mmol)
N-[3-(2-{3-[4-(4-nitro-phenyl)-imidazol-1-yl]-1,-
1-dimethyl-propylamino}-1-hydroxyethyl)-phenyl]-benzenesulphonamide,
0.10 g palladium on activated charcoal, and 30 mL methanol were
shaken in an autoclave at ambient temperature under a hydrogen
atmosphere of 1 bar for 3 h. The reaction mixture was filtered and
the filtrate was freed from solvent using the rotary evaporator.
1.59 g (3.05 mmol, 99%)
N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylamino}-1-
-hydroxyethyl)-phenyl]-benzenesulphonamide were obtained as a
colourless solid.
[0257] Examples 17, 32, 34 and 35 were synthesised analogously to
the method described in Example 8. The following compounds were
used instead of
N-[3-(2-{3-[4-(4-nitro-phenyl)-imidazol-1-yl]-1,1-dimethyl-propylamino-
}-1-hydroxyethyl)-phenyl]-benzenesulphonamide:
[0258] Example 17: benzyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hy-
droxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate
(Example 16)
[0259] Example 32:
N-[3-(2-{1,1-dimethyl-3-[3-(4-nitro-phenyl)-2-oxo-imida-
zolidin-1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
(Example 30)
[0260] Example 34:
N-[3-(2-{3-[4-(3,5-dimethyl-isoxazol-4-yl)-imidazol-1-y-
l]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
(Example 20)
[0261] Example 35:
N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imidazol-1--
yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
(Example 4)
EXAMPLE 12
Synthesis of
N-[3-(1-hydroxy-2-{3-[4-(4-N,N-dimethylsulphamylamino-phenyl)-
-imidazol-1yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamid-
e
[0262] 42
[0263] 0.064 mL (0.600 mmol) N,N-dimethylsulphamyl chloride was
added at 0.degree. C. to 0.208 g (0.400 mmol)
N-[3-(2-{3-[4-(4-amino-phenyl)-imida-
zol-1-yl]-1,1-dimethyl-propylamino}-1-hydroxyethyl)-phenyl]-benzenesulphon-
amide in 4 mL pyridine and the mixture was stirred for 16 h at
ambient temperature. The reaction mixture was poured into 50 ml
hydrochloric acid (1M)/ethyl acetate 1:1. The phases were separated
and the aqueous phase was extracted three times with 20 mL ethyl
acetate. The combined organic phases were dried over sodium
sulphate and the solvent was eliminated using the rotary
evaporator. The residue was purified by flash column chromatography
[methylene chloride/methanol (100:0->70:30)], and 0.131 g (0.209
mmol, 52%) N-[3-(1-hydroxy-2-{3-[4-(4-N,N-dimethylsulphamylamino-
-phenyl)-imidazol-1yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesul-
phonamide were obtained as a colourless solid.
[0264] The compounds of formula (IA) listed in Table 1 were
obtained, inter alia, analogously to the method described
above.
[0265] The abbreviation X.sub.2 used in Table 1 denotes a link to
the position in the general formula shown in Table 1 instead of the
corresponding groups R.sup.2.
1TABLE 1 43 Example R.sup.2 R.sub.f value MS 1 44 DCM/MeOH 85/15;
R.sub.f 0.52 ESI (M + H).sup.+ =505 2 45 DCM/MeOH/NH.sub.4OH
90/10/1; R.sub.f 0.50 ESI (M + H).sup.+ =537 3 46
DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.48 ESI (M + H).sup.+ =523 4
47 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.38 ESI (M + H).sup.+ =550
5 48 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.39 ESI (M + H).sup.+
=539 6 49 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.36 ESI (M +
H).sup.+ =535 7 50 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.30 ESI (M
+ H).sup.+ =521 8 51 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.32 ESI
(M + H).sup.+ =520 9 52 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.23
ESI (M + H).sup.+ =598 10 53 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f
0.34 ESI (M + H).sup.+ =555 11 54 DCM/MeOH 90/10; R.sub.f 0.20 ESI
(M + H).sup.+ =487 12 55 DCM/MeOH 90/10; R.sub.f 0.26 ESI (M +
H).sup.+ =627 13 56 DCM/MeOH 90/10; R.sub.f 0.26 ESI (M + H).sup.+
=524 14 57 DCM/MeOH/AcOH 70/30/3; R.sub.f 0.07 ESI (M + H).sup.+
=473 15 58 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.25 ESI (M +
H).sup.+ =506 16 59 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.34 ESI
(M + H).sup.+ =639 17 60 DCM/MeOH/AcOH 70/30/3; R.sub.f 0.57 ESI (M
+ H).sup.+ =549 18 61 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.34 ESI
(M + H).sup.+ =539 19 62 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.21
ESI (M + H).sup.+ =562 20 63 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f
0.21 ESI (M + H).sup.+ =524 21 64 DCM/MeOH/NH.sub.4OH 90/10/1;
R.sub.f 0.31 ESI (M + H).sup.+ =536 22 65 DCM/MeOH/NH.sub.4OH
90/10/1; R.sub.f 0.36 ESI (M + H).sup.+ =525 23 66 DCM/MeOH 90/10;
R.sub.f 0.29 ESI (M + H).sup.+ =523 24 67 DCM/MeOH 90/10; R.sub.f
0.29 ESI (M + H).sup.+ =524 25 68 DCM/MeOH 90/10; R.sub.f 0.23 ESI
(M + H).sup.+ =536 26 69 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.36
ESI (M + H).sup.+ =511 27 70 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f
0.32 ESI (M + H).sup.+ =548 28 71 DCM/MeOH/NH.sub.4OH 90/10/1;
R.sub.f 0.32 ESI (M + H).sup.+ =577 29 72 DCM/MeOH/NH.sub.4OH
90/10/1; R.sub.f 0.46 ESI (M + H).sup.+ =553 30 73
DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.42 ESI (M + H).sup.+ =568 31
74 DCM/MeOH 90/10; R.sub.f 0.21 ESI (M + H).sup.+ =550 32 75
DCM/MeOH/NH.sub.4OH 90/10/1;R.sub.f 0.33 ESI (M + H).sup.+ =538 33
76 RP-18 F 254 MeCN/H.sub.2O/AcOH 20/80/1; R.sub.f 0.33 ESI (M +
H).sup.+ =526 34 77 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.27 ESI
(M + H).sup.+ =494 35 78 DCM/MeOH/AcOH 80/20/2; R.sub.f 0.50 ESI (M
+ H).sup.+ =423 36 79 DCM/MeOH/NH.sub.4OH 90/10/1; R.sub.f 0.35 ESI
(M + H).sup.+ =551 37 80 RP-18 F 254 MeCN/H.sub.2O/ 1/1; R.sub.f
0.59 ESI (M + H).sup.+ =573 38 81 RP-18 F 254 MeCN/H.sub.2O/AcOH
250/250/1; R.sub.f 0.51 ESI (M + H).sup.+ =564
[0266] Abbreviations:
[0267] AcOH: glacial acetic acid
[0268] DCM: dichloromethane
[0269] MeCN acetonitrile
[0270] MeOH: methanol
[0271] NH.sub.4OH: conc. solution of ammonia in water
[0272] RP-18 F254: Merck reversed phase silica gel 18 F254 TLC
plate
[0273] Unless otherwise stated, all the R.sub.f values were
determined on Merck silica gel 60 F254 TLC plates.
[0274] Chemical names of the Examples (Example Nos. correspond to
the numbering used below):
[0275] 1)
N-(3-{2-[1,1-dimethyl-3-(4-phenyl-imidazol-1-yl)-propylamino]-1--
hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0276] 2) N-(3-{2-[1,1-dimethyl-3-(3-methyl-1,4-dioxo-3,4-di
hydro-1H-phthalazin-2-yl)-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesu-
lphonamide
[0277] 3)
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-phenyl-imidazolidin-1-yl)-propy-
lamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0278] 4)
N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imidazol-1-yl]-propy-
lamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0279] 5)
N-[3-(2-{3-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dim-
ethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0280] 6)
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-imidazol-1-yl]-1,1-di-
methyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0281] 7)
N-[3-(1-hydroxy-2-{3-[4-(4-hydroxy-phenyl)-imidazol-1-yl]-1,1-di-
methyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0282] 8)
N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1,1-dimethyl-propy-
lamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0283] 9)
N-[3-(1-hydroxy-2-{3-[4-(4-methanesulphonylamino-phenyl)-imidazo-
l-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0284] 10)
N-(3-{1-hydroxy-2-[3-(4-iodo-imidazol-1-yl)-1,1-dimethyl-propyl-
amino]-ethyl}-phenyl)-benzenesulphonamide
[0285] 11) methyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethyl-
amino]-3-methyl-butyl}-1H-imidazole-4-carboxylate
[0286] 12)
N-[3-(1-hydroxy-2-{3-[4-(4-N,N-dimethyl-sulphamoylamino-phenyl)-
-imidazol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonami-
de
[0287] 13)
N-(3-{2-[1,1-dimethyl-3-(2-oxo-3-pyridin-2-yl-imidazolidin-1-yl-
)-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0288] 14)
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]--
3-methyl-butyl}-1H-imidazole-4-carboxylic acid
[0289] 15)
N-(3-{2-[1,1-dimethyl-3-(4-pyridin-4-yl-imidazol-1-yl)-propylam-
ino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0290] 16) benzyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-et-
hylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate
[0291] 17)
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamin-
o]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoic acid
[0292] 18)
N-[3-(1-hydroxy-2-{3-[3-(4-hydroxy-phenyl)-2-oxo-imidazolidin-1-
-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0293] 19)
N-[4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethyla-
mino]-3-methyl-butyl}-1H-imidazol-4-yl)-phenyl]-acetamide
[0294] 20)
N-[3-(2-{3-[4-(3,5-dimethyl-isoxazol-4-yl)-imidazol-1-yl]-1,1-d-
imethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0295] 21)
N-[3-(1-hydroxy-2-{3-[4-(6-methoxy-pyridin-3-yl)-imidazol-1-yl]-
-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0296] 22)
N-[3-(2-{1,1-dimethyl-3-[4-(5-methyl-thiophen-2-yl)-imidazol-1--
yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0297] 23)
N-[3-(2-{3-[4-(4-fluoro-phenyl)-imidazol-1-yl]-1,1-dimethyl-pro-
pylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0298] 24)
N-(3-{2-[1,1-dimethyl-3-(5-nitro-benzoimidazol-1-yl)-propylamin-
o]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0299] 25)
N-[3-(1-hydroxy-2-{3-[4-(4-methoxy-phenyl)-[1.2.3]triazol-1-yl]-
-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0300] 26)
N-(3-{2-[1,1-dimethyl-3-(4-thiophen-2-yl-imidazol-1-yl)-propyla-
mino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0301] 27) N-[3-(2-{3-[4-(4-di
methylamino-phenyl)-imidazol-1-yl]-1,1-dime-
thyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0302] 28) ethyl
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-eth-
ylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate
[0303] 29)
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-2-oxo-imidazolidin-1-
-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0304] 30)
N-[3-(2-{1,1-dimethyl-3-[3-(4-nitro-phenyl)-2-oxo-imidazolidin--
1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0305] 31)
N-[3-(1-hydroxy-2-{3-[3-(4-methoxy-phenyl)-5-methyl-[1,2,4]tria-
zol-1-yl]-1,1-dimethyl-propylamino}-ethyl)-phenyl]-benzenesulphonamide
[0306] 32)
N-[3-(2-{3-[3-(4-amino-phenyl)-2-oxo-imidazolidin-1-yl]-1,1-dim-
ethyl-propyl-amino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0307] 33)
N-[3-(2-{3-[4-(1-acetyl-2-amino-propenyl)-imidazol-1-yl]-1,1-di-
methyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide
[0308] 34)
N-(3-{2-[3-(5-amino-benzoimidazol-1-yl)-1,1-dimethyl-propylamin-
o]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide
[0309] 35)
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]--
3-methyl-butyl}-1H-benzoimidazole-5-carboxylic acid
[0310] 36) ethyl
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethyla-
mino]-3-methyl-butyl}-1H-benzoimidazole-5-carboxylate
[0311] 37)
N-{3-[2-(1,1-dimethyl-3-{4-[4-(1H-tetrazol-5-yl)-phenyl]-imidaz-
ol-1-yl}-propylamino)-1-hydroxy-ethyl]-phenyl}-benzenesulphonamide
[0312] 38)
4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamin-
o]-3-methyl-butyl}-1H-imidazol-4-yl)-N-hydroxy-benzamide
[0313] The (R)- and (S)-enantiomers of the Examples may be obtained
from the racemate by chiral HPLC, for example (e.g. column:
Chirobiotic T, 250.times.4.6 mm obtained from Messrs Astec). The
mobile phase used may be methanol with 0.05% triethylamine and
0.05% acetic acid (eluant A) in acetonitrile. Silica gel with a
particle size of 5 .mu.m to which the glycoprotein teicoplanin is
covalently bound may be used as the column material. Of outstanding
importance according to the invention are the (R)-enantiomers of
general formula: 82
[0314] The following enantiomers were obtained, for example:
[0315] Example 4: (30% eluant A in acetonitrile):
[0316] retention time
[(R)-N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imi-
dazol-1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide]=25.-
5 min
[0317] retention time
[(S)-N-[3-(2-{1,1-dimethyl-3-[4-(4-nitro-phenyl)-imi-
dazol-1-yl]-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide]=30.-
0 min.
[0318] Example 8 (30% eluant A in acetonitrile):
[0319] retention time
[(R)-N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1-
,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide]=22.-
4 min,
[0320] retention time
[(S)-N-[3-(2-{3-[4-(4-amino-phenyl)-imidazol-1-yl]-1-
,1-dimethyl-propylamino}-1-hydroxy-ethyl)-phenyl]-benzenesulphonamide]=25.-
1 min.
[0321] Example 17: (30% eluant A in acetonitrile)
[0322] retention time
[(R)-4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-h-
ydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoic
acid]=11.4 min,
[0323] retention time
[(S)-4-(1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-h-
ydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoic
acid]=12.9 min.
[0324] Example 28: (50% eluant A in acetonitrile)
[0325] retention time ethyl
[(R)-4-(1-{3-[2-(3-benzenesulphonylamino-pheny-
l)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate]=13.2
min,
[0326] retention time ethyl
[(S)-4-(1-{3-[2-(3-benzenesulphonylamino-pheny-
l)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)-benzoate]=14.6
min.
[0327] As has been found, the compounds of general formula (I) are
characterised by their great versatility in the therapeutic field.
Particular mention should be made of those applications in which
the effects of beta-3-agonists, particularly selective
beta-3-agonists play a part.
[0328] Such diseases include for example:
[0329] atherosclerosis, cholangitis, gall bladder disease, chronic
cystitis, chronic bladder inflammation; chronic prostatitis,
cystospasm, depression, duodenal ulcer, duodenitis, dysmenorrhoea;
increased intraocular pressure and glaucoma, enteritis,
oesophagitis, gastric ulcer, gastritis, gastrointestinal disorders
caused by contraction(s) of the smooth muscle, gastrointestinal
disorders incl. gastric ulcer; gastrointestinal ulceration,
gastrointestinal ulcers, glaucoma, glucosuria, hyperanakinesia,
hypercholesterolaemia, hyperglycaemia, hyperlipaemia, arterial
hypertension, hypertriglyceridaemia, insulin resistance, intestinal
ulceration or small bowel ulcers (incl. inflammatory bowel
diseases, ulcerative colitis, Crohn's disease and
proctitis=inflammation of the rectum), irritable colon and other
diseases with decreased intestinal motility, depression,
melancholy, pollacisuria, frequent urinary urgency, nervous
neurogenic inflammation, neurogenic bladder dysfunction, neurogenic
inflammation of the respiratory tract, neuropathic bladder
dysfunction, nycturia, non-specific diarrhoea, dumping syndrome,
obesity, fatness, pancreatitis, inflammation of the pancreas,
stomach ulcers, prostate diseases such as benign prostatic
hyperplasia, enlarged prostate, spasm, cramp, type 2 diabetes
mellitus, irritable bladder or concrement of the lower urinary
tract.
[0330] The beta-3 agonists according to the invention are
particularly suitable for the treatment of obesity, insulin
resistance, type 2 diabetes mellitus, urinary incontinence,
irritable colon and other diseases with decreased intestinal
motility or depression, particularly for the treatment of diabetes
and obesity.
[0331] The activity of the beta-3 agonists can be determined for
example in a lipolysis test. The test procedure may be carried out
as follows:
[0332] Adipocytes were isolated from fatty tissue ex vivo by
modifying a method according to Rodbell (Rodbell, M. Metabolism of
isolated fat cells. I. Effects of hormones on glucose metabolism
and lipolysis. J Biol Chem 239: 375-380. 1964). The excised fatty
tissue was cut into small pieces and mixed with 1 mg/ml collagenase
in Krebs Ringer Buffer (KRB) containing 6 mM glucose and 2% albumin
by gently shaking for 30-40 min at 37.degree. C. The cells were
filtered through a gauze, washed twice with KRB and in each case
50-150 g were centrifuged for 5 min. 10 .mu.l of the centrifuged
adipocytes were incubated with 90 .mu.l of a compound according to
the invention (agonist) at concentrations of between 10.sup.-15 to
10.sup.-4 M. The agonists were incubated over 40 min at 37.degree.
C. A varying release of glycerol in the medium indicated that the
fat cell lipolysis had altered as a result of the addition of the
agonist. Released glycerol was detected enzymatically with a Sigma
kit (triglyceride (GPO Trinder) Reagent A; Cat. # 337-40A), as
described below.
[0333] Glycerol is phosphorylated by ATP via glycerol kinase. The
resulting glycerol-1-phosphate is oxidised by glycerolphosphate
oxidase to form dihydroxyacetone phosphate and hydrogen peroxide.
Then a quinonimine dye is produced by the peroxidase-catalysed
coupling of sodium-N-ethyl-N-(3-sulphopropyl)m-ansidine and
4-aminoantipyrine. The dye has an absorption peak at 540 nm. The
absorption is directly proportional to the glycerol concentration
in the samples.
[0334] The new compounds may be used for the prevention or
short-term or long-term treatment of the above-mentioned diseases,
and may also be used in conjunction with other active substances
used for the same indications. These include, for example,
antidiabetics, such as metformin, sulphonylureas (e.g.
glibenclamid, tolbutamide, glimepiride), nateglinide, repaglinide,
thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma
agonists (e.g. GI 262570), alpha-glucosidase inhibitors (e.g.
acarbose, voglibose), alpha2 antagonists, insulin and insulin
analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin.
Also, inhibitors of protein tyrosine phosphatase 1, substances
which influence deregulated glucose production in the liver, such
as e.g. inhibitors of glucose-6-phosphatase, or
fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon
receptor antagonists and inhibitors of phosphoenol pyruvate
carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase,
lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g.
simvastatin, atorvastatin), fibrates (e.g. bezafibrate,
fenofibrate), nicotinic acid and its derivatives, cholesterol
absorption inhibitors such as for example ezetimibe, bile
acid-binding substances such as for example cholestyramine,
HDL-raising compounds such as for example inhibitors of CETP or
regulators of ABC1 or active substances for the treatment of
obesity, such as e.g. sibutramine or tetrahydrolipostatin.
[0335] In particular, they may also be combined with drugs for
treating high blood pressure such as e.g. All antagonists or ACE
inhibitors, diuretics, .beta.-blockers, and other modulators of the
adrenergic system or combinations thereof. In addition,
combinations with stimulators of the adrenergic system via alpha 1
and alpha 2 and also beta 1, beta 2 and beta 3 receptors are
particularly suitable.
[0336] The compounds of general formula (I) may be used on their
own or in conjunction with other active substances according to the
invention, optionally also in conjunction with other
pharmacologically active substances. Suitable preparations include
for example tablets, capsules, suppositories, solutions,
particularly solutions for injection (s.c., i.v., i.m.) and
infusion, elixirs, emulsions or dispersible powders. The content of
the pharmaceutically active compound(s) should be in the range from
0.1 to 90 wt. %, preferably 0.5 to 50 wt. % of the composition as a
whole, i.e. in amounts which are sufficient to achieve the dosage
range specified below. The specified doses may be taken several
times a day, if necessary.
[0337] Suitable tablets may be obtained, for example, by mixing the
active substance(s) with known excipients, for example inert
diluents such as calcium carbonate, calcium phosphate or lactose,
disintegrants such as corn starch or alginic acid, binders such as
starch or gelatine, lubricants such as magnesium stearate or talc
and/or agents for delaying release, such as carboxymethyl
cellulose, cellulose acetate phthalate, or polyvinyl acetate. The
tablets may also comprise several layers.
[0338] Coated tablets may be prepared accordingly by coating cores
produced analogously to the tablets with substances normally used
for tablet coatings, for example collidone or shellac, gum arabic,
talc, titanium dioxide or sugar. To achieve delayed release or
prevent incompatibilities the core may also consist of a number of
layers. Similarly the tablet coating may consist of a number or
layers to achieve delayed release, possibly using the excipients
mentioned above for the tablets.
[0339] Syrups or elixirs containing the active substances or
combinations thereof according to the invention may additionally
contain a sweetener such as saccharine, cyclamate, glycerol or
sugar and a flavour enhancer, e.g. a flavouring such as vanillin or
orange extract. They may also contain suspension adjuvants or
thickeners such as sodium carboxymethyl cellulose, wetting agents
such as, for example, condensation products of fatty alcohols with
ethylene oxide, or preservatives such as p-hydroxybenzoates.
[0340] Solutions for injection and infusion are prepared in the
usual way, e.g. with the addition of isotonic agents, preservatives
such as p-hydroxybenzoates, or stabilisers such as alkali metal
salts of ethylenediamine tetraacetic acid, optionally using
emulsifiers and/or dispersants, whilst if water is used as the
diluent, for example, optionally organic solvents may optionally be
used as solvating agents or dissolving aids, and transferred into
injection vials or ampoules or infusion bottles.
[0341] Capsules containing one or more active substances or
combinations of active substances may for example be prepared by
mixing the active substances with inert carriers such as lactose or
sorbitol and packing them into gelatine capsules.
[0342] Suitable suppositories may be made for example by mixing
with carriers provided for this purpose, such as neutral fats or
polyethyleneglycol or the derivatives thereof.
[0343] Excipients which may be used include, for example, water,
pharmaceutically acceptable organic solvents such as paraffins
(e.g. petroleum fractions), vegetable oils (e.g. groundnut or
sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or
glycerol), carriers such as e.g. natural mineral powders (e.g.
kaolins, clays, talc, chalk), synthetic mineral powders (e.g.
highly dispersed silicic acid and silicates), sugars (e.g. cane
sugar, lactose and glucose) emulsifiers (e.g. lignin, spent
sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone)
and lubricants (e.g. magnesium stearate, talc, stearic acid and
sodium lauryl sulphate).
[0344] The preparations are administered by the usual methods,
preferably by oral or transdermal route, preferably oral. For oral
administration the tablets may, of course contain, apart from the
above-mentioned carriers, additives such as sodium citrate, calcium
carbonate and dicalcium phosphate together with various additives
such as starch, preferably potato starch, gelatine and the like.
Moreover, lubricants such as magnesium stearate, sodium lauryl
sulphate and talc may be used at the same time for the tabletting
process. In the case of aqueous suspensions the active substances
may be combined with various flavour enhancers or colourings in
addition to the excipients mentioned above.
[0345] For parenteral use, solutions of the active substances with
suitable liquid carriers may be used.
[0346] The dosage for intravenous use is from 1-1000 mg per hour,
preferably between 5 and 500 mg per hour.
[0347] However, it may sometimes be necessary to depart from the
amounts specified, depending on the body weight, the route of
administration, the individual response to the drug, the nature of
its formulation and the time or interval over which the drug is
administered. Thus, in some cases it may be sufficient to use less
than the minimum dose given above, whereas in other cases the upper
limit may have to be exceeded. When administering large amounts it
may be advisable to divide them up into a number of smaller doses
spread over the day.
[0348] The formulation Examples which follow illustrate the present
invention without restricting its scope:
EXAMPLES OF PHARMACEUTICAL FORMULATIONS
[0349]
2 A) Tablets per tablet active substance 100 mg lactose 140 mg corn
starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg
500 mg
[0350] The finely ground active substance, lactose and some of the
corn starch are mixed together. The mixture is screened, then
moistened with a solution of polyvinylpyrrolidone in water,
kneaded, wet-granulated and dried. The granules, the remaining corn
starch and the magnesium stearate are screened and mixed together.
The mixture is compressed to produce tablets of suitable shape and
size.
3 B) Tablets per tablet active substance 80 mg lactose 55 mg corn
starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone
15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400
mg
[0351] The finely ground active substance, some of the corn starch,
lactose, microcrystalline cellulose and polyvinylpyrrolidone are
mixed together, the mixture is screened and worked with the
remaining corn starch and water to form a granulate which is dried
and screened. The sodiumcarboxymethyl starch and the magnesium
stearate are added and mixed in and the mixture is compressed to
form tablets of a suitable size.
4 C) Ampoule solution active substance 50 mg sodium chloride 50 mg
water for inj. 5 ml
[0352] The active substance is dissolved in water at its own pH or
optionally at pH 5.5 to 6.5 and sodium chloride is added to make it
isotonic. The solution obtained is filtered free from pyrogens and
the filtrate is transferred under aseptic conditions into ampoules
which are then sterilised and sealed by fusion. The ampoules
contain 5 mg, 25 mg and 50 mg of active substance.
* * * * *